
















A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial 
fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of 









Linda S. Adair 
Margaret E. Bentley 





































Charlotte Lane: Growth in HIV-exposed and -uninfected infants in Malawi and Rwanda 
(Under the direction of Linda S. Adair) 
 
 Background: Infants are considered to be HIV-exposed and -uninfected (HEU) if they are 
exposed to the virus during pregnancy, delivery, and breastfeeding, but do not acquire HIV. 
These infants may be at increased risk of poor health outcomes, including growth. 
 Methods: This dissertation considers the growth of HEU infants in the Breastfeeding, 
Antiretroviral, and Nutrition study in Malawi and the Kigali Antiretroviral and Breastfeeding 
Assessment for the Elimination of HIV in Rwanda. These studies both enrolled HIV-positive 
pregnant and/or postpartum women and followed their HEU infants in resource restricted, urban 
settings. We first compare the growth trajectories of infants in these two countries through the 
use of SuperImposition by Translation and Rotation and latent class growth mixture modeling. 
We then consider the longitudinal interrelationship between maternal viral suppression, 
maternal weight change, breastfeeding, and infant growth through structural equation modeling. 
Finally, we investigate the relationship between inflammatory burden, measured through a latent 
variable, and growth.  
 Results:  We show some similarities in the growth patterns of HEU infants from Malawi 
and Rwanda. However, neonatal WAZ, maternal height, and maternal age, have different 
relationships with growth in these two contexts. In Kabeho, positive postpartum maternal weight 
change is related to longer infant length. Years the mother was on antiretroviral treatment and 
maternal viral suppression are related to smaller length at three months. Among BAN infants, 





variable by exposure to maternal supplementation and antiretroviral medications. The effect of 
inflammation on infant length is likely chronic and altered by the cause of inflammation.  
  Conclusion: Public health officials should consider the unique risk factors for poor health 
in their own context when designing interventions to support the wellbeing of HEU infants. There 
may be long-term effects of exposure to antiretroviral therapy on infant growth that must be 
considered as well. We show that HIV-treatment approaches and inflammation may interact and 
relate to infant growth outcomes. More work is needed to further establish the effects of 
exposure to HIV and antiretroviral medications on infant growth in the modern era of widespread 
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CHAPTER 1: INTRODUCTION 
Overview 
Massive strides in the treatment and prevention of HIV have been achieved over the last 
several decades as a result of an incredible, international research and humanitarian effort. 
Because of this work, HIV positive individuals now remain healthy for years after diagnosis. HIV-
positive women survive and are healthy long enough to have children who remain largely 
uninfected. The HIV-negative infants of HIV-positive women are termed HIV-exposed and –
uninfected (HEU). Before the widespread availability of antiretroviral therapy (ART), these 
infants were at increased risk of early morbidity and mortality. However, with better treatment 
options, there is hope that the health of HEU infants may also be improving.  
Here, we examine the growth of HEU infants as a proxy for their health and wellbeing. 
Growth may be either a determinant of future health or a marker of an underlying process which 
is also related to future outcomes. In either case, growth is essential for future health and 
wellbeing. First, we compare growth trajectories between two populations of HEU infants born in 
different countries and decades to understand similarities and differences in their patterns of 
development. Then, we consider the interrelationship between viral suppression, maternal 
weight change, breastfeeding, and infant growth. Finally, we examine the relationship between 
inflammation and growth within this at risk population. 
We hope that this work can contribute to the current understanding of the health and 
wellbeing of HEU infants in the modern era of widespread ART availability. It demonstrates 
some similarities in the development of these infants and highlights risk factors for poor growth 
in this population. It is part of an ongoing effort to understand the developmental patterns of 





Objectives and specific aims 
 The objective of this dissertation is to examine the growth of HEU infants in Rwanda 
and Malawi in order to improve our understanding of the current state of HEU infant health and 
identify factors associated with poor outcomes in this population. We consider infants who 
participated in the Kigali Antiretroviral and Breastfeeding Assessment for the Elimination of HIV 
(Kabeho) and the Breastfeeding, Antiretroviral, and Nutrition (BAN) studies. Kabeho took place 
in Kigali, Rwanda from April 2013 to January 2015 and enrolled 608 HIV-positive, pregnant or 
early postpartum women participating in prevention of mother-to-child HIV transmission 
programs in selected high-volume facilities. The BAN study followed 2,373 treatment naive, 
pregnant, HIV-positive women in Lilongwe, Malawi from March 2004 to February 2009.  
Aim 1: Compare the growth trajectories of the infants in the BAN and Kabeho studies. 
Aim 1a: Use SuperImposition by Translation and Rotation (SITAR) to compare the mean size 
and growth velocities of infants in the BAN and Kabeho studies. Aim 1b: Use latent class 
growth mixture modeling to examine underlying growth patterns in these populations. Aim 1c: 
Examine the relationships between established risk factors for poor growth and the identified 
infant growth trajectories. Premise: Mean growth trajectories in both the BAN and Kabeho 
studies indicate low average length-for-age z-scores (LAZ) and elevated average weight relative 
to height. However, the full extent of the similarities in growth patterns across contexts has not 
been established. Similar growth despite meaningful contextual differences would imply a 
common phenotype of discordant growth among HEU infants.  
Aim 2: Determine the relationship between viral suppression, maternal weight change, 
breastfeeding, and infant growth within Kabeho infants through the use of structural equation 
modeling. Premise: The health and wellbeing of mothers and their infants are inevitably linked, 
especially through nutrition and breastfeeding. These four factors have the potential to feedback 





Aim 3: Determine the relationship between inflammatory burden and HEU infant growth 
within BAN infants. Premise: Because inflammation affects growth and HEU infants have 
altered patterns of inflammation, the relationship between inflammation and growth within this 
population may be different than that of the general population.  
Datasets 
 We examine HEU infant growth in two studies: the Breastfeeding, Antiretroviral, and 
Nutrition (BAN) study and the Kigali Antiretroviral and Breastfeeding Assessment for the 
Elimination of HIV (Kabeho). The use of these two studies allows for the examination of HEU 
infant growth in two disparate contexts and allow the research questions drive the methods 
rather than the data determining the research question. Each study has its own context, 
strengths, and limitations. Study protocols are presented and compared in table 1.  
BAN 
The primary purpose of the BAN (Breastfeeding, Antiretroviral, and Nutrition) study was 
to investigate the effectiveness of antiretroviral therapy in preventing mother-to-child 
transmission of HIV. The study also examined the impact of maternal supplementation during 
lactation on maternal health. BAN occurred under an older set of recommendations for the 
prevention of mother-to-child transmission of HIV and feeding of HIV-exposed and -uninfected 
infants. The use of this dataset allows for an examination of growth trajectories under low 
resource, high medical access conditions in which breastfeeding was quickly ended at six 
months. As a trial, BAN allows for the examination of the effects of three different treatment 
regimens. The intense level of study observation in BAN may have induced mothers to behave 
in non-standard ways regarding their own health and that of their infants. Participants were 
provided with free medical care at the study clinic. 
The BAN study enrolled 2,373 pregnant, HIV-positive, treatment naive women in 
Lilongwe, Malawi between March 2004 and February 2009. Women were asked to exclusively 





randomized to three HIV treatment groups (no treatment, infant antiretroviral therapy, or 
maternal antiretroviral therapy) and two nutrition groups (lipid nutrient supplement or no 
supplement); however, the no treatment groups were closed in March 2008. At this point, 
mothers in the no treatment arms had the opportunity to switch into either of the two active 
treatment arms. In addition, starting in December 2005, infants were given prophylactic 
cotrimoxizole. BAN study visits took place at 1, 2, 4, 6, 8, 12, 18, 21, 24, 28, 36, 42, and 48 
weeks. At each visit, weight was measured using Tanita digital infant scales; length was 
measured with length boards made to United Nations International Children’s Emergency Relief 
Fund specifications; and mothers were asked about recent infant illnesses. Socioeconomic and 
other characteristics were collected from mothers at baseline. 
Kabeho 
The Kabeho Study (Kigali Antiretroviral and Breastfeeding Assessment for the 
Elimination of HIV) was designed as an observational study of the implementation of universal, 
lifelong ART for all pregnant or breastfeeding, HIV-positive women (Option B+). Kabeho likely 
has less bias introduced due to intense observation and the heavy use of medical facilities. In 
addition, it allows for an understanding of infant growth in the context of a longer duration of 
breastfeeding. Women were encouraged to breastfeed for at least a year. 
Kabeho enrolled 608 HIV-positive, pregnant or postpartum women participating in 
prevention of mother-to-child HIV transmission programs in selected high-volume health 
facilities in Kigali, Rwanda. Enrollment in the Kabeho study took place from April 2013 to 
January 2014. All women were placed on lifelong antiretroviral therapy (Option B+). Women 
were required to have documented HIV infection, plan to remain in the Kigali area after delivery, 
and provide consent. Study visits were conducted at the health facilities within two weeks of 
birth; at six, 10, and 14 weeks; monthly from four to 18 months; and at 21 and 24 months. Birth 
weight was measured by birth attendants in the clinical settings where births took place. If 





as a measure of neonatal weight. At each visit, trained nurses took duplicate measures of infant 
length to the nearest centimeter (cm) using Shorr boards, and weight to the nearest 10 grams 
using United Nations International Children’s Relief Fund scales. Maternal weight was 
measured at six, 12, 18, and 24 months. Viral load was measured at birth, 18 months, and 24 
months. Viral load testing was conducted using the Roche Cobas Ampli-Prep/Cobas TaqMan 
HIV-1 quantitative test. The lower limit of detection for this test is 20 copies/ml. 
Country level context 
Both studies took place in low income countries in sub-Saharan Africa. These countries 
have agriculture based economies with most of their populations living in rural settings.1,2 They 
have high rates of infectious diseases.1,2 However, each country is unique, with a different level 
of resources, culture, and socioeconomic context. These differences must be considered when 
interpreting results. Table 2 provides basic data related to HIV and maternal and infant health 
for the two countries.  
According to the Human Development Index, Malawi is less developed than Rwanda. 
Because BAN is also older than Kabheo, we expect that the living conditions were more 
challenging in BAN than Kabeho. Breastfeeding is nearly universal in Malawi; however, only 
34% of infants four to five months of age are exclusively breastfed.3 Many women report 
difficulties exclusively breastfeeding their infants for six months, in accordance with 
recommendations, due to poor support or understanding of its sufficiency.4 HIV-positive women 
worry that breastfeeding may accelerate the progression of their disease.5 Only 51% of women 
attend the recommended four antenatal care visits.6 Women report barriers to facility based 
delivery, including labor during night, financial constraints, and rainy season.6 They also report 
moderate control over their own income, assets, and movement.3 
In Rwanda, 81% of infants four to five months of age are exclusively breastfed.7  As a 
consequence of the war, women’s empowerment is quite strong in Rwanda. Women are 





are well informed about treatment for childhood diarrhea, with 89% being aware of the use of 
oral rehydration salts.7 Lack of financial resources and distance to the clinic can prevent women 











Table 1: Comparison of the BAN and Kabeho studies 
  BAN Kabeho 
Full name Breastfeeding, antiretroviral, and nutrition study 
Kigali antiretroviral and 
breastfeeding assessment for the 
elimination of HIV 
Location Lilongwe, Malawi Kigali, Rwanda 
Years 2004-2009 2013-2014 
Study design Randomized controlled trial Observational study 
Sample size 
2,373 mother-infant pairs total 
608 mother-infant pairs 
348 mother on treatment and nutrition 
supplement 
336 mother on treatment with no 
nutrition supplement 
ART regimen 
600 mg zidovudine Variable 
300 mg lamivudine Mostly reverse transcriptase 
inhibitors 400 mg lopinavir or 100 mg ritonavir 
Timing of 
study visits 
1, 2, 4, 6, 8, 12, 18, 21, 24, 28, 36, 42, 
and 48 weeks 
2,6,10,14 weeks; monthly from 4-18 
months; 21 and 24 months 
Infant weight 
Duplicate measures by a trained 
nurse using a Tanita digital infant 
scale at each study visit 
Duplicate measures by a trained 
nurse using a UNICEF scale at each 
study visit 
Infant length 
Duplicate measures by a trained 
nurse using a length boards mate to 
UNICEF specifications at each study 
visit 
Duplicate measures by a trained 





Collected at baseline through 
questionnaire 




Asked current breastfeeding, and 
whether any foods or liquids were fed 
Asked whether currently 
breastfeeding, and what liquids and 
solids infant received since last visit. 
ART 
Adherence Counted remaining pills 
Asked number of missed doses in 
the last three days 
Maternal 
weight  Measured at each study visit 
Duplicate measures on standing 
scale at 6, 12, 18, and 24 months 
Illness 
episodes 
 Maternal report of illnesses since last 
visit, physician physical examination 
at each visit, and pharmacy logs of all 
medications prescribed, with 
indication 
Binary variable representing an 







Table 2: Country level comparison of Malawi and Rwanda 
 Malawi Rwanda 
Ranking in Human Development Index 1718 1588 
HIV infection among adults 9.6%1 2.7%2 
Average number of infants per woman 5.51 4.62 
Life expectancy at birth  63.71 67.52 
Children under five who are underweight 11.7%1 8.1%2 
Children 4-5 months exclusively breastfed 34.1%3 80.8%7 
Children under six months exclusively breastfed 61%3 87%7 






CHAPTER 2: LITERATURE REVIEW  
In 2018, there were 37.9 million people infected with HIV.9 Each week, 6,200 women 
ages 15 to 24 became infected.9 These women have the potential to transmit HIV to their infants 
during pregnancy, delivery, and breastfeeding. However, with improved treatment options, 
mother-to-child transmission of HIV is decreasing and more infants remain exposed but 
uninfected.10,11 New infections among children declined by 41% from 2010 to 2018.9  Because 
the population of HEU infants is increasing, their wellbeing is a major public health concern.11 
The failure of such a large number of individuals to reach their full human potential would not 
only be a major humanitarian injustice but would also have serious economic and social impacts 
worldwide.  
The effects of HIV exposure on infant health are uncertain; however, HEU infants are 
likely at increased risk of morbidity and mortality compared to their unexposed 
counterparts.10,12,13 Much of this increased risk may be due to environmental and socioeconomic 
factors that co-vary with HIV; nonetheless, the increased risk of morbidity and mortality 
experienced by HEU infants cannot be fully explained by differences in maternal care, 
breastfeeding, or vertical transmission of pathogens.10 HEU infants may have reduced immune 
capacity, causing an increased risk of infection.13 Other factors, including the direct biological 
action of the virus or antiretroviral medications could also affect infant health. In addition, these 
infants may experience a growth pattern characterized by slow linear growth without a 
concordant decrease in weight gain, resulting in a slightly elevated weight relative to length.14–16 
This discordant growth pattern could have detrimental long term health consequences as slow 






The importance of growth 
It is as yet unclear if growth represents a direct determinant of future health or an 
indicator of another process which also determines future outcomes.17 Regardless, early 
development is related to long term health and wellbeing.25 The restricted nutrient supply and 
frequent infections which cause stunting may also cause alterations in brain development, 
leading to poor cognitive outcomes.17 Infant growth is related to a many future outcomes 
including: school attainment, productivity, cognitive development, wages, obesity, insulin 
resistance, blood pressure, and more.18 Individuals with faster weight-gain in the first two years 
of life tend to complete more years of school and have a lower risk of failure in school in low and 
middle income countries.23 Stunting by two to three years of age is related to poorer cognitive 
development and school attainment.24 Supplementation to improve children’s nutritional status 
can also improve motor development, mental development, and cognitive ability.24 Maternal 
stunting increases the risk of poor pregnancy outcomes.17  
Early growth is related to future metrics of body composition.19,20,26,28,29 Once weight 
elevation develops, it tends to persist; therefore, it is necessary to prevent weight elevation from 
birth.19 Infant growth affects childhood body mass index (BMI), total body fat, and abdominal 
fat.27 Childhood obesity is highly correlated with adult obesity and related morbidities.30 
Furthermore, childhood overweight status is related to immediate metabolic abnormalities, 
including elevated cholesterol, triglycerides, and glucose; increased risk of type II diabetes; and 
high blood pressure.30 Despite the seriousness of the consequences of early life obesity, there 
is a lack of knowledge about prevention of obesity in the period from birth to two years.19  
 
The relationship between growth and nutrition 
It is widely understood that nutrition influences growth. Without food, infants cannot 
grow. With too much of certain foods, infants become overweight children and adults. Early 





permanent epigenetic changes influencing health outcomes in later life.31 A variety of 
approaches to improve growth have been suggested, including dietary diversification and 
supplementation; however, the impacts of interventions to support these changes are 
inconsistent.32  
The first source of nutrition that most infants receive is breastmilk. The results of studies 
considering breastfeeding practices and infant growth are highly variable depending on the 
metric of growth considered, the quantification of breastfeeding, timing, study design, local 
cultural practices, and more.33–38 Although there is conflicting evidence suggesting a relationship 
between breastfeeding and infant growth, a major limitation of these studies is the possibility for 
reverse causation. Women tend to adjust their breastfeeding status to perceived infant health 
and cues from the infant. As such, these studies should be interpreted cautiously. Breastfeeding 
has a variety of other positive impacts including decreased exposure to pathogens, protective 
immunological effects, and improved cognitive outcomes as well as potential health benefits for 
the mother.39  
The first solid foods infants receive have significant impacts on growth as well.30 Dietary 
diversity from six to 23 months is related to growth.37,40 In Ghana, the consumption of eggs, 
dairy, and legumes is related to increased LAZ.41 A randomized controlled trial that provided 
infants with an egg a day found significant increases in LAZ and weight-for-age z-score (WAZ) 
and decreases in stunting and underweight status over a six month period in Ecuador.42 
However, a similar study in Malawi, which also provided an egg a day, found no effect, likely 
due to the large amount of animal source foods already in the diet.43 Another study in Malawi 
randomized infants to receive a cowpea, common bean, or corn-soy based daily food 
supplements from six to 12 months.44 LAZ decreased least in the cowpea group. 
Lipid nutrient supplements (LNS) are often used in interventions to prevent growth 
faltering and support the health, wellbeing, and energy balance of the mother-infant dyad. 





and/or the infant to support healthy growth. However, in Malawi, providing small quantity LNS to 
mothers from pregnancy to six months postpartum and their infants from six to 18 months did 
not result in improved infant growth relative to an iron-folic acid or micronutrient supplement.45,46 
A study in Burkina Faso found that small quantity lipid nutrient supplements from nine to 18 
months of age may improve growth; however, the intervention group had additional access to 
medical care relative to the control.47 The type of LNS used appears to have no effect on 
growth. There are limited differences in the growth outcomes of infants on milk, soy, or corn-soy 
supplements in Malawi.48 In addition, no difference exist in growth or body composition of 
Cambodian infants at 18 months on four different supplements: rice, fish, and spiders; rice and 
fish; corn and soy; corn, soy, and milk.49  
Growth in HEU infants 
HEU infants may be particularly vulnerable to poor growth outcomes due to a unique set 
of harmful exposures: increased risk of maternal illness and death, deleterious socioeconomic 
factors that co-vary with HIV infection, reduced immune function, increased pathogen exposure, 
and exposure to HIV and antiretroviral medications.10,11,13,50–53 There is some, highly conflicted 
evidence indicating that HEU infants may grow more slowly than unexposed infants.10,11,54–57 
Much of the lack of clarity regarding HEU infant growth is due to the highly variable and rapidly 
changing treatment regimens to which they are exposed. 
Little research has been published relating nutrition to growth within HEU infants in low 
resource settings. Nonetheless, there has been a call to provide micronutrient supplements to 
HEU infants to support growth.58 This suggestion is largely due to the decreased bone mineral 
density observed in HEU infants but also due to the possibility of disrupted growth patterns. 
Maternal supplementation with LNS after delivery has no effect on HEU infant growth from zero 
to 24 weeks in Malawi, but may be associated with increased LAZ from 24 to 28 weeks.15,59 





weight-for-age.60 Traditional complementary foods may be inadequate to support healthy growth 
in Rwandan, HEU infants.16  
The effect of HIV and ART exposure on growth remains unknown.10 A 2016 review of 
perinatal and postnatal exposure to maternal HIV and combination antiretroviral therapy found 
“modest but significant impairment of [neuro]development and a higher risk of growth 
impairment” related to HIV and combination antiretroviral therapy exposure.12 Authors also 
concluded that HEU infants experienced higher risk of morbidity and mortality compared to HIV-
unexposed, -uninfected (HUU) infants. A 2018 meta-analysis similarly concluded that HEU 
children have slower neurodevelopment than HUU children and HEU children exposed to ART 
have slower development than those not exposed to ART.61 However, a recent study from 
Botswana found no difference in neurodevelopment between HEU and HUU infants and further 
found no differing effects of triple antiretroviral treatment or zidovudine.62 
Specific antiretroviral therapies are, however, associated with alterations in infant 
growth. Infants whose mothers were randomized to triple antiretroviral therapy have lower LAZ 
and WAZ at 24 months than infants whose mothers received zidovudine at least 2 weeks before 
birth and breastfed for six months in Botswana.63 Infants on tenofovir have lower WAZ and LAZ 
in the first year of life compared to infants whose mothers received combination antiretroviral 
therapy.64 In both studies, treatment assignment was random and not based on HIV disease 
progression. As such, it is highly probable that the antiretroviral medication itself altered infant 
growth.  
Recent studies have shown that HEU infants experience a mean growth pattern of low 
LAZ and slightly elevated weight relative to length.14–16 In the study that included HUU infants as 
a comparator, the unexposed infants were larger in WAZ, LAZ, WLZ, and BMI z-score than the 
HEU infants.14 From six to eight months, HEU infants from the BAN study in Malawi and the 
Kabeho study in Rwanda were shorter and relatively heavier than the sample in the 





these differences were largely closed between Kabeho infants and other Rwandan infants, but 
remained apparent in Malawi. We examine the similarities and differences in the growth 
trajectories of infants participating in the BAN and Kabeho studies in Aim 1.  
Understanding the discordant growth pattern 
The occurrence of low LAZ and high WLZ in the same infant is counterintuitive as we 
associate linear growth faltering with a nutritional deficit and overweight status with a nutritional 
excess. Nonetheless, stunting and overweight both represent forms of malnutrition.65 The co-
occurrence of these two problems is increasing in developing countries, particularly in children 
from one to five years of age.65 In Indonesia, the prevalence of concurrent stunting and 
overweight status is increasing with one of the largest risk factors being the year in which an 
infant was born.66 A similar pattern exists in South African children from 1.5 to five years of age. 
BMI and LAZ are significantly correlated, with 68% of obese children but only 14% of normal or 
underweight children being stunted.67 Among Ghanaian children from zero to five months of 
age, LAZ and WLZ are inversely correlated, but they are positively related from 12 to 47 
months.68 Factors predicting stunting and wasting are variable with some overlapping (birth 
weight, wealth index, age) and some only significant for one metric of malnutrition (number of 
antenatal care visits, parity, maternal height, urban / rural setting).68 Nonetheless, a study in 
Ecuador found no association between stunting and overweight status.69 
The biological mechanisms separately and concurrently driving linear and ponderal 
growth are not yet fully understood. However, socioeconomic status, maternal occupation, and 
maternal education are related to concurrent stunting and overweight.65 Among Ecuadorian 
children, living in a household that sells livestock is a risk factor for both overweight and 
stunting.69 Kenyan infants on a multiple micronutrient powder including iron are heavier but not 
taller than those on a similar supplement without iron, indicating the possibility that some 
micronutrients act on weight gain without supporting linear growth.70 In rural Malaysia, children 





low BMI.71 This is likely due to the fact that an energy dense diet is related to lower intake of 
fruits and dairy products, which support growth. But, the energy dense diet is higher in fish, 
meat, and legumes, foods that also support healthy growth. 
Inflammation and growth 
The factors which affect early inflammation and immune development are also not fully 
understood. However, the development of infants’ immune systems is likely driven by the need 
to protect the fetus and infant, support feto-maternal tolerance, and allow for microbial 
colonization where appropriate.72 Evidence from mouse studies indicates that the maternal 
microbiota may significantly influence immune development.73 The mother may actually start 
transferring bacterial antigens to the fetus in utero to support immune development.74 There is 
conflicting evidence regarding the effect of cytokines in milk on early infant immune 
development.75  
The mechanisms linking inflammation and growth are not well established. Effects in 
children with chronic inflammatory conditions indicate abnormalities in the growth hormone / 
insulin-like growth hormone-1 axis and the action of cytokines on growth plates.76 Both 
interlukin-6 and cortisol, which are elevated during inflammatory responses, have been directly 
linked to growth outcomes through certain biochemical pathways.77 Alternatively, the energetic 
demands of mounting immune responses may cause the association between inflammation and 
poor growth.77 Chronic inflammation of the intestinal mucosa may influence nutrient absorption, 
with adverse effects on infant growth.78–81 
HEU infants have different immune and inflammatory profiles than HUU infants.82–85 
There has been some suggestions that the drug regimens HEU infants are exposed to may alter 
their inflammatory profiles.13,86–88 Among HEU infants, elevation in certain inflammatory markers 
at birth is related to lower weight at birth and six months.85 However, the relationship between 





necessary to consider the relationship between inflammation and growth in the context of the 
various treatment regimens HEU infants are exposed to (Aim 3). 
Development of treatment protocols for mothers with HIV and their infants 
The rapid changes in protocols for the prevention of mother-to-child transmission of HIV 
and HEU infant feeding in low resource settings may explain some of the variation in study 
findings regarding HEU infant health and growth. The World Health Organization (WHO) 
published guidelines in 2000, 2004, and 2006 specifying treatment protocols and CD4 (cluster 
of differentiation 4) cut points for treatment eligibility.89 In 2010, the WHO proposed new 
guidelines for the prevention of mother-to-child transmission of HIV.90 These guidelines 
specified that all HIV-positive, pregnant or breastfeeding women in low resource settings should 
receive antiretroviral therapy from 14 weeks gestation until one week after the cessation of 
breastfeeding. Women would then only continue treatment if it was needed for their own health. 
However, in 2011, a call was put out in the Lancet to adopt universal, lifelong antiretroviral 
therapy for all pregnant, HIV infected women.91 Several justifications for this approach were 
explained: CD4  counts are not widely available in low income countries; the high fertility rates in 
many of these settings result in women repeatedly starting and stopping treatment; the 
messaging and logistics of lifelong antiretroviral treatment are simpler; and many women do not 
receive their first prenatal visit before 14 weeks. As a result, the WHO quickly published a new 
set of guidelines in 2012.90 These guidelines included Option B+, the adoption of universal, 
lifelong antiretroviral treatment for all HIV-positive, pregnant or breastfeeding women. The WHO 
explained that this new approach would simplify service delivery, protect against transmission in 
future pregnancies, reduce HIV transmission to partners, and avoid stopping and starting 
treatment. Early estimates predicted the adoption of Option B+ would be more cost effective 
than the previously recommended treatment approaches in real world scenarios by both 





B+ would have benefits in terms of efficacy and effectiveness in preventing transmission, 
improving maternal health, increasing safety, supporting adherence, and avoiding resistance.93    
At the same time that these guidelines were developed, the WHO also published advice 
on the feeding of infants born to HIV-positive mothers in low resource settings. In 2001 and 
2006 the WHO published recommendations stressing the potential harms of breastfeeding in 
the context of HIV and supported sharing this information with the mother while supporting her 
to make an informed decision.94,95 These recommendations were significantly revised in 2010 
and updated with minimal changes in 2016.96 The WHO now recommends that HIV-positive 
women in these settings exclusively breastfeed their infants for six months and continue 
breastfeeding for at least a year. Breastfeeding should stop only once an adequate and safe 
diet can be established without breastmilk.  
In the context of ART and exclusive breastfeeding, mother-to-child transmission can be 
reduced to 1% in low income settings; however, the 93% HIV-free survival rate found in Kigali, 
Rwanda may more accurately reflect survival in most real world contexts.97,98 Among infants 
negative for HIV at six weeks, exclusively breastfed HIV-exposed infants in South Africa had a 
transmission rate of 4%.99 A recent systematic review noted that transmission rates ranged from 
1.1% to 15.1% and have recently begun to rise.100  
Maternal viral suppression, maternal weight change, breastfeeding, and infant growth 
The adoption of the new recommendations for the prevention of mother-to-child 
transmission of HIV and feeding of HEU infants in low resource settings is expected to have 
several biological and behavioral consequences that may affect both maternal and infant health.  
Improved treatment may result in increased viral suppression. Maternal viral suppression 
may improve HEU infant growth. Among South African women, mothers with lower absolute 
CD4 have infants with lower birth WAZ than women with high absolute CD4; these infants then 
grow faster after birth.101 Infants born to women with viral loads above 1,000,000 copies/ml 





South Africa and Brazil examining the effect of different antiretroviral treatments and requiring 
infants to be formula fed.102 This indicates the possibility that these infants may experience 
slower growth as well. In contrast, neither CD4 nor viral load at enrollment were related to infant 
WAZ or LAZ in a study examining the effects of combination antiretroviral therapy or zidovudine 
on infant growth in Botswana.103  
As discussed above, exclusive breastfeeding for six months, as recommended by the 
WHO, may affect infant growth. However, in the context of HIV, some women may chose not to 
breastfeed or to wean early due to concerns about transmission and/or their own health.5 
Despite being beneficial for infants, breastfeeding can induce significant energetic demands on 
the mother, and women may mobilize fat stores to meet this demand.104 One study in Botswana 
found that only 9% of HEU infants were ever breastfed while over 99% of unexposed infants 
were breastfed.62  
HIV infection itself is associated with weight loss and wasting.105 Weight loss among 
HIV-positive individuals is associated with increased mortality risk.106 Maternal weight loss is 
expected in the postpartum period.107–109 The rate of weight loss decreases as time passes after 
birth. The effect of maternal weight on postnatal, infant growth is still unknown,110 especially in 
the context of HIV. Low maternal, gestational mid-upper arm circumference (MUAC) is 
associated with slower infant growth in WAZ and LAZ in Tanzania.111 Among female infants in 
BAN, low maternal BMI combined with maternal weight loss was related to decreased infant 
weight gain and linear growth relative to other combinations of these risk factors.112 Continued 
maternal weight loss from six months to two years postpartum may be related to maternal 
disease severity and affect HEU infant growth through the horizontal transmission of disease or 
decreased ability to care for the infant. We develop a structural equation model in Aim 2 to 
better understand the relationship between viral suppression, maternal weight change, 


























LAZ 6-8 mo. -0.7 -0.9  -0.99 -1.23 
LAZ 9-11 mo.  -1.0 -1.1  -1.01 -1.55 
WLZ 6-8 mo. 0.3 0.2  0.67 0.36 




Chapter 3: SIMILAR GROWTH TRAJECTORIES AMONG HIV-EXPOSED AND -
UNINFECEDTED INFANTS IN THE BAN AND KABEHO STUDIES 
 
Summary 
Background: With the success of treatment for HIV, mother-to-child transmission of the 
disease is decreasing. Increasingly, efforts are being focused on supporting the health and 
wellbeing of the HIV-exposed and -uninfected (HEU) infants born to HIV-positive women.   
Methods: We pool data from two studies of HEU infants: the BAN study in Malawi and 
the Kabeho study in Rwanda. We then use SITAR and latent class mixture modeling to 
determine if infants from the two countries experience similar patterns in growth.  
Results: Infants from the Malawi cohort had, on average, lower weight than Rwandan 
infants; however, length, linear growth velocity, and the rate of weight gain were similar. Each 
latent class was composed of 40-60% infants from each cohort, except for the largest class, 
which was predominantly infants from Rwanda. Increasing maternal height was related to 
increased odds of being in the tallest classes. Among Rwandan infants, maternal height was 
also related to increased size in length and weight. Increasing neonatal WAZ was associated 
with increased odds of being in the largest length and weight classes in both studies. Neonatal 
WAZ also was also positively related to size in length and weight and accelerated ponderal 
growth. However, the effect sizes were variable by country of origin. 
Conclusion: Although there are some similarities in the growth patterns of the HEU 
infants in these two settings, the effects of risk factors for poor growth, including low maternal 
height and neonatal WAZ, are not the same across settings. As such, researchers and policy 







Success in the treatment of HIV has resulted in more HIV-positive women living long and 
healthy lives. Along with improved antiretroviral treatment (ART) options, mother-to-child 
transmission of HIV is decreasing and efforts to support the health of HIV-exposed and -
uninfected (HEU) infants are increasing in low- and middle-income countries.10 These infants 
are believed to be at increased risk of severe morbidity and mortality.13,51,113 Relative to the 
World Health Organization (WHO) standards, HEU infants may be at risk of larger deficits in 
linear growth than ponderal growth, resulting in high weight-for-length z-scores (WLZ).14–16  
This discordant growth pattern could have detrimental long-term consequences. Linear 
growth and relative weight gain through infancy are associated with childhood fat and fat-free 
mass.26 Deficits in infant linear growth are related to a variety of cognitive and wellbeing 
measures.18 Childhood obesity is related to a poor outcomes, including impaired 
cardiorespiratory fitness, decreased motor skills, and decrease quality of life.114   
We must understand whether distinct populations of HEU infants experience similar 
patterns of discordant growth in order to improve efforts to support the health and wellbeing of 
HEU infants. Research and policy initiatives are actively ongoing in nearly every country across 
the world and under a variety of different treatment regimens for the prevention of mother-to-
child transmission of HIV. Therefore, it is of utmost importance that we determine the extent to 
which findings from one context can be generalized to another. Similar growth trends despite 
considerable differences in the socioecological context and HIV-treatment approach may 
suggest a common phenotype of discordant growth among HEU infants. 
The purpose of this paper is to compare the growth of HEU infants in the Breastfeeding, 
Antiretroviral, and Nutrition (BAN) study in Lilongwe, Malawi and the Kigali Antiretroviral and 
Breastfeeding Assessment for the Elimination of HIV (Kabeho) in Kigali, Rwanda to determine if 






BAN was designed as a clinical trial before universal, lifelong ART was introduced, 
whereas Kabeho was a longitudinal observational study of the implementation of Option B+, the 
WHO initiative to provide all HIV-positive pregnant and lactating women lifelong ART.90 The 
WHO expected that this new approach would simplify service delivery, protect against 
transmission in future pregnancies, reduce HIV transmission to partners, and avoid stopping 
and starting treatment. All women participating in BAN were treatment naive, but some women 
in Kabeho had been on treatment for years. The countries in which these studies took place 
have meaningfully different levels of development, with Rwanda ranking 158th (out of 189) and 
Malawi ranking 171st on the Human Development Index.8 BAN started about ten years before 
Kabeho. These differences provide the socio-environmental variation which allows for a cross-
context comparison of growth outcomes.  
We investigate if there are similarities in the growth trajectories of these infants despite 
the significant differences in the study context. We first determine if infants in these two 
populations show similar mean size and velocity of growth through SuperImpostion by 
Translation and Rotation (SITAR) analysis. We then examine if there are similarities in the 
underlying (latent) growth patterns observed in these populations. We also examine the 
relationship between known risk factors for poor growth and observed growth trends in these 
two populations to determine if these factors act similarly across contexts.  
Materials and methods 
Participants 
The Kabeho study enrolled 608 HIV-positive, pregnant or early postpartum women 
participating in prevention of mother-to-child HIV transmission programs in selected high-
volume health facilities in Kigali, Rwanda. Of these, 563 infants remained in the study to 
contribute repeated growth measures. Enrollment in the Kabeho study took place from April 





required to have documented HIV infection, plan on remaining in the Kigali area after delivery, 
and provide consent.  
The BAN study enrolled 2,373 treatment naïve, pregnant, HIV-positive women in 
Lilongwe, Malawi between March 2004 and February 2009. Women were randomized to three 
treatment arms (maternal ART, infant ART, and no treatment) and two nutrient supplement 
arms (lipid nutrient supplement or no supplement). To balance sample size and match treatment 
regimens between the studies, only the 530 women who were randomized to receive ART and 
enrolled after the beginning of the use of prophylactic cotrimoxizole in December 2005 were 
included in this analysis.115 One of the primary goals of the study was to assess the feasibility of 
exclusive breastfeeding for six months followed by rapid weaning, and women were counseled 
to follow this pattern.115 
Additional information regarding study visits, data collection, and variable specification is 
provided in supplemental materials one.  
Data analysis 
We use two methods to examine growth: SITAR and latent class growth mixture 
modeling. These two methods are used because they allow for the examination of different 
aspects of growth. First, through SITAR, we compare the absolute, mean growth trends of these 
populations. Then, we use latent class growth mixture modeling to identify sub-groups of infants 
who experience similar patterns in the development of their linear deficits and relative weight 
excess compared to the WHO standard using z-scores. Both approaches allow for testing if 
baseline characteristics, such as country of origin, predict growth outcomes.  
SuperImposition by Translation and Rotation (SITAR)  
In SITAR,116,117 a mean growth trajectory is first estimated for the population. Then, for 
each infant, coefficients for size, timing, and velocity are estimated relative to the mean. In our 





velocity and the timing parameter is not estimated. Sex was included in the estimation of the 
coefficients to allow for sex-specific differences in these coefficients where this improved model 
fit. Additional information regarding model specification and interpretation is provided in 
supplemental materials two.  
SITAR can be used to determine if two populations experience similar patterns in growth 
using the following steps:116  
1. Run SITAR on the combined dataset and estimate coefficients for each infant. Use a t-
test to compare the mean values of the coefficients between the two populations.  
2. The SITAR model is then re-estimated, including population membership as a fixed 
effect for the estimation of each coefficient (size and velocity). 
3. If coefficients are different, SITAR is then fitted on each population separately to 
illustrate differences in the population mean curves.  
In order to examine potential differences in the effect of known risk factors for poor growth 
by country of origin, we return to step one and test the relationship between these factors and 
the estimated size and velocity coefficients. The risk factors examined here are infant sex; 
neonatal WAZ; maternal CD4 at infant birth, height, age, and parity; and adherence to 
recommendations for exclusive breastfeeding and treatment. An interaction is included to allow 
these variables to have different relationships based on country of origin. This allows us to 
determine if factors known to be related to growth have similar relationships with the size and 
velocity of growth across populations of HEU infants.  
Latent growth trajectories 
Latent class growth mixture modeling is used when there is reason to believe that there 
is heterogeneity in growth patterns within a study sample. It allows for the identification of sub-
populations with similar developmental trajectories. Standard growth modeling techniques, 





from Rwanda and Malawi) come from the same underlying distribution (that of HEU infants). 
However, this may not be the case if the underlying biological mechanisms and risk factors 
affecting the outcomes function differently in the two populations.118 For this analysis, repeated 
measures of weight and length at the same visit were averaged and converted to z-scores using 
the WHO growth standards.119 Z-scores are used here due to differences in the timing of 
measurements which are less problematic in SITAR models.  
Latent class models used the lcmm package in R to identify characteristic infant growth 
trajectories for WLZ and LAZ.120 The number of latent classes was determined based on 
Baysian information criterion (BIC), class size, and graphical plotting to maintain a sufficient 
number of infants per class to power the later analysis while maximizing the number of classes 
developed. Infants are assigned to the class to which they have the highest probability of 
belonging. Then, multinomial logistic regression is used to estimate odds of latent class 
membership. The same set of baseline characteristics considered in the SITAR models is used 
here; however, these models are constructed in a stepwise fashion to separately examine the 
effects of baseline characteristics alone and then add-in characteristics that develop postnatally. 
This is because latent class growth mixture modeling assigns class membership from birth, and 
factors that develop after birth cannot affect class membership before they develop. As such, 
the interpretation of the effects of these postnatal factors must be more cautious.  
Results 
Sample population 
Figure 1 shows that infants from Malawi have similar length to those from Rwanda; 
however, Malawian infants weigh less. When length and weight are converted to the z-score 
scale, differences in LAZ become accentuated. This effect may be the result of sex-specific 
growth patterns combined with non-significant differences in the sex composition of these 





disease and reflecting their naïve treatment status. Adherence to the exclusive breastfeeding 
recommendation was higher in Malawi, but adherence to treatment was lower.  
SITAR 
Step 1: Estimate SITAR on the combined sample of infants from Malawi and Rwanda 
The linear growth SITAR model with the best fit includes a log transformation of infant 
age in months and two degrees of freedom. Female infants are shorter than males (-1.07 cm, 
p<0.001) and grow at a slower linear velocity (-0.03, p=0.003). In weight, the best fitting model 
includes log transformations of both weight and age. Due to the log transformation of weight, the 
size coefficient is multiplied by 100 and interpreted as a percentage. Female infants are lighter 
than males (-7.54%, p<0.001), but there is no difference in velocity. Therefore, sex is removed 
from the estimation of the velocity parameter to improve model fit. Average length, weight, and 
the respective velocities are plotted in figure 2. While linear growth velocity appears to have a 
smoothly parabolic decline, weight velocity shows a steep decline just before six months of age.   
Relative to Rwandan infants, Malawian infants have smaller length-size coefficients 
(p<0.001). Differences in length-velocity coefficients approach statistical significance (p=0.06). 
Although Rwandan infants tend to have larger weight-size coefficients than Malawian infants 
(p<0.001), there is no difference in the weight-velocity parameter (p=0.88).  
Step 2: Estimation of SITAR model including fixed effect for country 
Based on results from the previous step, models for linear growth were re-run including 
a binary variable for country of origin as a fixed effect in the estimation of the size and velocity 
coefficients. Being Malawian is associated with smaller mean length (size= -0.46 cm, p<0.001), 
but, once this is accounted for, there is no difference in mean linear growth velocity (p=0.11).  
For weight, results from step one show size but not velocity varies by country of origin; 





ponderal growth model. Infants from Malawi are lighter than those from Rwanda (size = -4.60%, 
p<0.001).   
Step 3: Estimation of SITAR within each individual dataset 
SITAR models were fit separately for Malawian and Rwandan infants. Linear growth 
velocities in the two populations are similar and cross several times. In contrast, Malawian 
infants have a faster weight gain velocity early in life, but also experience a more rapid decline 
in velocity than Rwandan infants. However, for much of the study period, weight gain velocities 
are similar.   
Predictors of SITAR coefficients by study membership 
Infants with higher neonatal WAZ and taller mothers have larger mean size in length and 
weight than those with smaller neonatal WAZ and shorter mothers (Table 5). The effect of 
neonatal WAZ is more pronounced in Malawian infants, but the effect of maternal height is less 
in Malawian infants. Taller mothers tend to have infants with relatively accelerated linear growth. 
Infants of older mothers tend to have shorter average length and weight and slower linear 
growth. In Malawi, older mothers also have infants with accelerated ponderal growth. Once 
these factors are accounted for, infants in the Malawian cohort have larger mean size in length 
than those in the Rwandan cohort.  
Latent growth trajectories 
Four linear growth trajectory classes were identified (Figure 3). Trajectories are roughly 
parallel, and represent persistent length differences apparent at birth. All trajectories have 
declines in average z-score of approximately one unit in the first year of life. The largest class, 
class three, consists of 38% of the study sample. It has a mean z-score of -1.1 at birth and -1.8 
by 12 months (Table 6). 
Five trajectory classes were identified  for WLZ. Three are roughly parallel, have 





z-scores. The largest class, class three, consisted of 33% of the study sample (Table 7). Mean 
z-score was 0.4 at one month and declined to -0.3 by 12 months.  
Predictors of class membership 
The three classes with LAZ less than zero include approximately equal proportions of 
infants from Malawi and Rwanda (Table 6). Females and infants with higher neonatal WAZ, 
taller mothers, and mothers with a primary school education are less likely to be in the shortest 
LAZ class. Infants with taller mothers and with higher neonatal WAZ are more likely to be in the 
two tallest LAZ classes. The effect of neonatal WAZ in increasing odds of being in the two tallest 
classes is more pronounced in Malawian infants than Rwandan infants. Infants with older 
mothers are less likely to be in the tallest class.  
Four of the five WLZ classes have similar proportions of infants from Malawi and 
Rwanda (Table 7). Although the highest WLZ class is predominantly infants from Rwanda, 
country of origin does not significantly predict class membership. Increased neonatal WAZ 
increases odds of being in the heaviest class. Adherence to breastfeeding recommendations or 
treatment did not affect these results, as such, results from these models are not presented.  
Because two sets of parallel trends were identified, a post hoc probit was conducted to 
examine the relationship between these same variables and belonging to a class with 
decreasing WLZ relative to classes with increasing WLZ. Infants with taller mothers have lower 
odds of decreasing WLZ (OR = 0.988). Increasing neonatal WAZ is also related to decreasing 
odds of decreasing WLZ (OR = 0.868), with a smaller effect among Malawian infants (OR = 
0.891). Having a mother who completed primary school increased the odds of belonging to a 
class with decreasing WLZ (OR = 1.188) among Rwandan infants. But, but the effect was 
reversed among Malawian infants (OR = 0.833).   
Discussion 
These data show that HEU infants from Malawi and Rwanda have some similarities in 





gain, and underlying patterns in growth trajectories. However, these infants had differences in 
risk factors that are context specific. The relationships between maternal height and neonatal 
WAZ and growth patterns varied by country. Although infants from the two countries have 
different mean sizes, once differences in mean size were accounted for in step two of the 
SITAR analysis, length and weight velocities are not different between the studies. The bottom 
panels of figure 2 show that the length, length velocity, and weight velocities of these two 
populations are similar over much of the study period. Absolute weight is somewhat lower 
among Malawian infants.  
Neonatal WAZ, maternal height, and maternal age are significantly related to infant 
mean size, and a subset of these factors are also related to growth velocity. This is consistent 
with a large body of literature which finds these factors to be related to infant growth. Similarly, 
among Nigerian infants of unknown HIV status, maternal age and birthweight are related to rate 
of weight gain in the first 45 days of life after controlling for maternal HIV status; however, 
maternal height is not related to weight gain.121 Importantly, these factors do not have consistent 
effects in Rwanda and Malawi, as indicated by several statistically significant interaction terms. 
In Rwanda, a one unit increase in neonatal WAZ is related to a 0.49 cm increase in mean 
length; however, in Malawi, the effect is more than doubled, reaching 1.08 cm. A one centimeter 
increase in maternal height is related to a 0.13 cm increase in mean length among Rwandan 
infants, but only a 0.06 cm increase in length among Malawian infants. In contrast, a variety of 
baseline characteristics, including maternal height, were found to have similar effects on size 
estimated through SITAR in Portugal, Italy, and Chile.122 However, we conclude that risk factors 
for poor growth may have different magnitudes of effects on population-level, mean growth 
outcomes among HEU infants in Malawi and Rwanda. This difference in results could be due to 
a larger variation in the environment and maternal health in our study than the previous analysis 





After comparing mean growth outcomes, we further investigated the latent growth 
patterns within these populations. The latent growth trajectory groups are similar among infants 
from both studies. In length and relative weight, most of the trajectory classes developed are 
composed of 40-60% infants from each study. The highest LAZ and WLZ classes have lower 
representation of Malawian infants, but this relationship is not statistically significant. This is 
consistent with the findings from the SITAR analysis which indicate that Malawian infants have 
lower mean size. Therefore, we conclude that mean and sub-group patterns in growth between 
these two populations are generally similar, with Malawian infants being somewhat smaller than 
Rwandan infants.  
The parallel trends in linear growth indicate patterns of infant linear growth are largely 
determined pre- or perinatally and there is strong tracking. In contrast, work limited to the 
Kabeho study identified one class of infants that did not track but crossed another class and 
became shorter on average.16 However, in the combined sample, this class is not identified, 
likely due to the smaller number of classes which were found. Similar tracking was not observed 
for relative weight. WLZ-classes one and two have approximately equal mean WLZ at one 
month, but diverge rapidly thereafter. This implies the possibility of a perinatal or early postnatal 
exposure which alters the weight gain patterns of these infants.  
Many of the same factors that predicted the SITAR growth coefficients in our study also 
related to odds of growth class membership. Previously, these factors were found to be related 
to latent class membership within the Rwandan cohort as well.16 However, the effect of neonatal 
WAZ is actually more pronounced in Malawian infants.  
Given the type of analysis performed, we cannot determine if differences in growth 
patterns and risk factors are due to differences in HIV-disease severity, study design, ART, or 
sociodemographic factors. Determining the cause of the differences is outside of the scope of 
this paper. We do, however, show that well established risk factors for poor growth do not have 





important for the development of programs and policies to support the health and wellbeing of 
HEU infants. It re-affirms the importance of tailoring interventions to each setting and context. 
Factors that put an infant at risk in one setting may have a different effect in another setting. The 
identification of at risk infants will help with the targeting of interventions. Policy makers must 
use extreme caution when borrowing approaches from seemingly similar contexts as the 
ultimate impact could be quite different. While interventions can be adopted from other contexts, 
they should always be re-evaluated in new settings. Future studies should compare the growth 
trajectories of HEU infants in similar contexts but exposed to different treatment regimens and in 
different contexts but exposed to similar treatment regimens to disentangle the effects of the 
environment form those of treatment approaches. 
This paper has several strengths and limitations. The longitudinal nature of both of these 
studies allows for the detailed analysis of growth trajectories, rather than limiting analysis to 
growth endpoints. However, 210 infants were lost to follow-up over the study periods resulting in 
these infants not being represented at later time periods. Both methods employed here are 
robust to missing data and retain infants in the model for the periods for which they contribute 
data. Because the studies did not include unexposed infants, it is not possible to determine if 
similar results would have been observed in an unexposed population. We believe that this, 
while possible, does not undermine our findings. The findings may apply equally to unexposed 
infants, but that is a question for further research. For now, we limit our conclusions to the HEU 








We conclude that, while there are some similarities in growth patterns between these 
two populations of HEU infants, the risk factors for poor growth have different magnitudes of 
effects in these two populations. Therefore, it is important that researchers and policy makers 
consider the unique needs of each population of HEU infants. Discussion of HEU infant growth 
as a single, cohesive topic should be limited because risk factors for poor growth are not the 
same across contexts. As such, the HEU infants likely to experience poor growth are also likely 







Table 4: Descriptive statistics of the study sample 
 
 
 Malawi  Rwanda  Full sample  P-value2  
  N / Mean % / SD1   N / Mean % / SD   N / Mean % / SD   
Total N 530 NA  563 NA  1093 NA  NA 
Female 263 49.62%  296 52.58%  559 51.14%  0.36 
Neonatal WAZ -0.523 0.91  -0.71 1.26  -0.62 1.10  <0.01 
CD4 count per µl 477.46 191.62  575.16 237.53  524.60 220.37  <0.01 
First birth 54 10.19%  104 18.47%  158 14.46%  <0.01 
Maternal Height (cm) 157.16 5.14  157.20 6.35  157.18 5.79  0.22 
Maternal Age (years) 26.49 5.07  29.46 6.05  28.02 5.79  <0.01 
Adherent to EBF4 463 87.36%  317 56.31%  780 71.36%  <0.01 
Adherent to treatment 444 83.77%   520 92.36%   964 88.20%   <0.01 
1. Standard deviation  
2. Means were compared across sites using t-tests and chi-squared tests as appropriate. 






Table 5: Predictors of SITAR coefficients 
 Length 
  Size coefficient  Velocity coefficients 
  Coeff
1 SE2 P-value  Coeff SE P-value 
From Malawi 8.4663 3.225 0.009  -0.179 0.225 0.428 
Being female -0.080 0.161 0.618  0.012 0.011 0.295 
 From Malawi -0.044 0.222 0.841  -0.013 0.016 0.386 
Neonatal WAZ 0.488 0.067 <0.0001  -0.002 0.005 0.740 
 From Malawi 0.594 0.110 <0.0001  -0.011 0.008 0.149 
Maternal height 0.125 0.013 <0.0001  0.003 0.001 0.002 
 From Malawi -0.065 0.020 0.001  0.000 0.001 0.794 
Maternal age -0.035 0.015 0.020  -0.002 0.001 0.030 
 From Malawi 0.039 0.022 0.076  0.002 0.002 0.124 
First pregnancy -0.094 0.236 0.690  0.016 0.016 0.328 
 From Malawi 0.122 0.362 0.737  0.016 0.025 0.539 
CD4 count 0.000 0.000 0.981  0.000 0.000 0.198 
 From Malawi 0.000 0.001 0.488  0.000 0.000 0.240 
Maternal education: referent is did not complete primary school 
Completed primary  0.330 0.175 0.060  0.022 0.012 0.076 
 From Malawi -0.147 0.294 0.617 
 0.017 0.021 0.394 
Completed secondary  0.479 0.336 0.155  -0.032 0.024 0.174 
 From Malawi -0.171 0.418 0.684  0.069 0.029 0.019 
Adherence to 
treatment 0.073 0.162 0.654 
 -0.004 0.011 0.756 
 From Malawi 0.262 0.278 0.346 
 0.015 0.019 0.437 
Adherence to EBF -0.082 0.301 0.786  0.007 0.021 0.722 






  Size coefficient  Velocity coefficients 
  Coeff SE P-value  Coeff SE P-value 
From Malawi 0.274 0.190 0.149  -0.254 0.327 0.437 
Being female -0.007 0.009 0.486  0.010 0.016 0.543 
 From Malawi 0.002 0.013 0.886  -0.028 0.007 <0.0001 
Neonatal WAZ 0.032 0.004 <0.0001  -0.029 0.011 0.010 
 From Malawi 0.022 0.006 0.001  0.001 0.001 0.479 
Maternal height 0.004 0.001 <0.0001  0.001 0.002 0.568 
 From Malawi -0.003 0.001 0.021  -0.001 0.002 0.545 
Maternal age -0.002 0.001 0.037  0.002 0.002 0.424 
 From Malawi 0.002 0.001 0.063  0.056 0.024 0.019 
First pregnancy -0.012 0.014 0.380  -0.024 0.037 0.512 
 From Malawi 0.014 0.021 0.505  0.000 0.000 0.741 
CD4 count 0.000 0.000 0.568  0.000 0.000 0.895 
 From Malawi 0.000 0.000 0.823  0.012 0.018 0.483 
Maternal education: referent is did not complete primary school   
Completed primary  0.007 0.010 0.496  0.024 0.030 0.429 
 From Malawi 0.010 0.017 0.568  0.013 0.034 0.696 
Completed secondary  0.016 0.020 0.427  0.013 0.042 0.753 
 From Malawi -0.003 0.025 0.908  0.003 0.016 0.832 
Adherence to 
treatment 0.013 0.010 0.160 
 0.005 0.028 0.857 
 From Malawi 0.007 0.016 0.669 
 -0.033 0.030 0.275 
Adherence to EBF -0.010 0.018 0.559  0.036 0.037 0.333 
  From Malawi 0.016 0.021 0.447  -0.021 0.023 0.354 
1. Coefficient 
2. Standard error 





Table 6: Description of latent length-class and odds of class membership 
 Descriptive characteristics of each length-class 
   Class 1  Class 2  Class 3  Class 4 
   N / Mean % / SD
1   N / Mean % / SD  N / Mean % / SD   N / Mean % / SD 
Total N 120 11%  396 36%  407 37%  169 15% 
Female 73 61%  226 57%  204 50%  56 33% 
From Malawi 38 32%  177 45%  233 57%  82 49% 
Neonatal WAZ 0.00 1.12  -0.33 1.03  -0.77 0.98  -1.38 1.07 
CD4 517.44 226.92  537.51 211.70  511.67 223.17  531.24 228.51 
First birth 20 17%  56 14%  48 12%  34 20% 
Maternal Height (cm) 161.06 5.91  158.03 5.38  156.33 5.36  154.46 5.88 
Maternal Age (years) 28.05 5.66  28.33 5.68  27.96 5.77  27.48 6.19 
Adherent to EBF2 79.0 66%  288 73%  290 71%  122 72% 






Odds of length-class membership by baseline characteristics 
   Class 1  Class 2  Class 3  Class 4 
   OR3 P-value  OR P-value  REF  OR P-value 
From Malawi 47.751 0.651  0.197 0.737  REF  0.001 0.287 
Female  1.413 0.292  1.184 0.466  REF  0.339 0.0014 
 From Malawi 1.655 0.350  1.271 0.451  REF  1.484 0.367 
Neonatal WAZ 1.514 0.004  1.322 0.006  REF  0.632 0.000 
 From Malawi 6.573 0.000  1.808 0.001  REF  0.723 0.143 
Maternal height 1.206 0.000  1.062 0.004  REF  0.921 0.003 
 From Malawi 0.954 0.371  0.999 0.982  REF  1.045 0.267 
Maternal age 0.941 0.047  0.983 0.430  REF  1.026 0.377 
 From Malawi 1.030 0.583  1.016 0.615  REF  0.939 0.143 
First pregnancy 0.862 0.756  1.077 0.827  REF  1.200 0.681 
 From Malawi 5.023 0.057  1.374 0.560  REF  1.476 0.532 
CD4 count 0.999 0.228  1.000 0.586  REF  0.999 0.251 
 From Malawi 1.001 0.667  1.001 0.053  REF  1.002 0.108 
Maternal education: referent is did not complete primary school 
 Completed primary 1.340 0.403  0.772 0.298  REF  0.491 0.042 
  From Malawi 1.114 0.888  1.017 0.967  REF  1.117 0.845 
 Completed secondary 1.376 0.604  0.858 0.758  REF  0.331 0.205 
    From Malawi 1.215 0.834   0.877 0.827   REF   1.376 0.748 
1. Standard deviation 
2. Exclusive breastfeeding 
3. Odds ratio 







Table 7: Description of latent weight-class and odds of class membership 
 Descriptive characteristics of each weight-class 
   Class 1  Class 2  Class 3   Class 4  Class 5 





















Total N 158 14%  275 25%  365 33%  149 14%  145 13% 
Female 70 44%  121 44%  197 54%  84 56%  87 60% 
From Malawi 47 30%  129 47%  208 57%  63 42%  83 57% 
Neonatal WAZ -0.35 1.19  -0.59 1.07  -0.74 1.05  -0.40 1.12  -0.89 1.09 
CD4 574.46 263.30  508.56 220.99  517.80 208.05  527.46 210.22  514.49 202.85 
First birth 24 15%  33 12%  59 16%  21 14%  21 14% 
Maternal Height (cm) 157.81 5.93  156.24 6.18  157.02 5.30  157.83 6.11  158.01 5.55 
Maternal Age (year) 28.37 5.93  28.08 5.67  27.78 5.88  28.41 5.91  27.81 5.53 
Adherent to EBF2 109 69%  194 71%  265 73%  105 70%  106 73% 
Adherent to 
treatment 






Odds of weight-class membership by baseline characteristics         
   Class 1  Class 2  Class 3  Class 4  Class 5 
   OR3 P-value  OR P-value  REF  OR P-value  OR P-value 
From Malawi 0.075 0.691  0.021 0.443  REF  0.001 0.281  0.005 0.400 
Female  0.674 0.153  0.641 0.091  REF  1.491 0.193  1.793 0.109 
 From Malawi 0.925 0.858  1.094 0.798  REF  0.605 0.239  0.625 0.298 
Neonatal WAZ 1.425 0.0034  1.184 0.124  REF  1.176 0.201  0.834 0.193 
 From Malawi 1.111 0.643  1.033 0.852  REF 
 1.376 0.134  1.080 0.709 
Maternal height 1.012 0.597  0.968 0.128  REF 
 1.008 0.758  1.024 0.398 
 From Malawi 0.994 0.889  1.012 0.694  REF  1.038 0.333  1.030 0.443 
Maternal age 0.966 0.187  0.972 0.255  REF  0.984 0.552  0.965 0.279 
 From Malawi 1.060 0.182  1.046 0.194  REF  1.029 0.493  1.053 0.238 
First pregnancy 0.840 0.660  0.607 0.201  REF  0.766 0.546  0.769 0.593 
 From Malawi 0.890 0.883  1.114 0.851  REF  1.597 0.486  0.816 0.769 
CD4 count 1.000 0.940  0.999 0.23  REF 
 1.000 0.765  1.000 0.673 
 From Malawi 1.001 0.280  1.00 0.599  REF 
 1.000 0.898  1.001 0.532 
Maternal education: referent is did not complete primary school 
 Completed primary 0.795 0.450  1.411 0.221  REF 
 0.985 0.962  1.053 0.894 
  From Malawi 1.774 0.340  0.676 0.385  REF 
 1.279 0.663  0.770 0.641 
 Completed secondary 2.601 0.115  2.034 0.276  REF  1.431 0.619  3.133 0.094 
    From Malawi 0.372 0.232   0.518 0.380   REF   0.784 0.780  0.347 0.185 
1. Standard deviation 
2. Exclusive breastfeeding 
3. Odds ratio 









































































Mean WLZ over time




















Supplemental materials 1: Additional information regarding study visits, data collection, and 
variable specification.  
Kabeho study visits were conducted at the health facilities within two weeks of birth; at 
six, 10, and 14 weeks; monthly from four to 18 months; and at 21 and 24 months. At the six-
week visit, infants started prophylactic cotrimoxazole in accordance with the recommendations 
of the government of Rwanda at the time. Because the BAN study ended at 48 weeks, only data 
from the first year of life was included in this analysis. Birth weight was measured by birth 
attendants in the clinical settings where births took place. If recorded birth weight was not 
available, we used measurements taken at the first Kabeho visit as a measure of neonatal 
weight. At each visit, trained nurses took duplicate measures of infant length to the nearest 
centimeter (cm) using Shorr boards, and weight to the nearest 10 grams using United Nations 
International Children’s Relief Fund scales. Women self-reported ART adherence over the last 
three days. Women were also asked if they were currently breastfeeding and if they had given 
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BAN infant study visits took place at 0, 1, 2, 4, 6, 8, 12, 18, 21, 24, 28, 36, 42, and 48 
weeks. At each visit, weight was measured using Tanita digital infant scales; and length was 
measured with length boards made to United Nations International Children’s Emergency Relief 
Fund specifications. Women were asked to self-report adherence to ART over the previous 
three days. Women were also asked if they were currently breastfeeding and if other foods or 
liquids were being fed to their infants.  
Adherence to ART and exclusive breastfeeding guidelines were defined as non-time 
varying variables and included in a subset of the regression models. Because the number of 
visits, and therefore days reported on, varied by woman, adherence was defined as reporting 
taking >90% of all doses reported on for the first 6.5 months. This was to avoid penalizing 
women with more visits and more opportunities to miss a dose. Women with one, two, or three 
visits had to report 100% adherence to be considered adherent while those with four, five, or six 
visits could miss one dose and still be considered adherent. Adherence was calculated by 
dividing the number of days for which a dose was reported as missed by the total number of 
days for which women reported on adherence. Adherence to exclusive breastfeeding guidelines 
was defined as not reporting feeding the infant liquids or solids before six months of age. 
Because this question was phrased to refer to the entire period since the last visit, there was no 
need to correct for the differing number of visits.   
 
Supplemental materials 2: Additional information regarding SITAR model specification and 
interpretation.  
Models can be specified with varying functional forms in both the age and growth 
metrics. The log transformation corresponds to a relative stretching of the axis at larger values. 
If this transformation is applied to the dependent variable, the coefficient is not interpreted in 
absolute terms, but as a fractional change which, when multiplied by 100, becomes a 




estimation of the spline curve used to estimate the population mean to allow for more or less 
curvature. Models were selected based on fit statistics (adjusted BIC values) and the distribution 
of residuals. This method is designed to handle differences in the timing of measurements, so z-
scores are not needed. Furthermore, because the size in centimeters of a z-score changes over 
time, velocity measured in z-scores has a different, and less biologically relevant, meaning than 
the absolute measures which we employ in SITAR. Models were estimated in the SITAR 
package in R.117  
The three estimated coefficients represent three ways by which infant growth curves can 
be transformed to most closely match the mean growth curve. The size coefficient represents  
up-down shifting of the entire curve and reflects the mean size of the infant relative to the 
population. The velocity coefficient represents a shrinking-expanding of the growth curve. A 
positive value reflects accelerated growth. This value is interpreted as a fractional multiplier and 
does not have units. The timing coefficient represents a right-left shifting of the growth curve 






CHAPTER 4: LONGITUDIANL INTERRELATIONSHIPS BETWEEN HIV VIRAL 
SUPPRESSION, MATERNAL WEIGHT CHANGE, BREASTFEEDING, AND LENGTH IN HIV-
EXPOSED AND -UNINFECTED INFANTS IN THE KABEHO STUDY IN RWANDA 
 
Summary 
Background: Because HIV has become a chronic condition, the health of HIV-negative 
infants exposed to the virus is a major public health concern. To understand the effect of 
maternal HIV on infant health, we investigate the interrelationship between maternal viral 
suppression, maternal weight change, breastfeeding, and infant growth among HIV-exposed 
and -uninfected infants.  
Methods: The Kabeho study followed 608 HIV-positive pregnant and postpartum women 
attending HIV clinics in Kigali, Rwanda for 24 months. We use a structural equation model to 
investigate the dynamic relationships between viral suppression, maternal weight change, 
breastfeeding, and infant length-for-age z-score (LAZ).  
Results: Older mothers are more likely to be virally suppressed and to breastfeed. Viral 
suppression and the mother being on treatment for a longer period are related to lower infant 
LAZ at three months. A more positive maternal weight change is related to higher infant LAZ at 
the end of each period. The relationship between breastfeeding and LAZ is variable by infant 
age. 
Conclusion: The health of the mother-infant dyad is interlinked through HIV-specific 
pathways. There is a complex interrelationship between viral suppression, maternal weight 






As HIV becomes a chronic condition, more infants are born that are HIV-exposed, but 
unifected. Their infants are considered to be HIV-exposed and –uninfected (HEU) if they never 
acquire the disease. Success in the management of HIV has significantly reduced mother-to-
child transmission of the disease, so more infants remain HEU.10 However, HEU infants 
continue to be at increased risk of early morbidity and mortality.10,12,13 Therefore, there is a 
growing public health focus on the wellbeing of the uninfected infants born to HIV-positive 
mothers.10,124  
Linear growth is one aspect of infant health and wellbeing. Growth can be viewed as 
either a determinant of future health or as a marker of an underlying process which also 
determines future outcomes.17,125 Regardless, early development is essential for success later in 
life.25 Infant growth is related to school attainment, productivity, cognitive development, wages, 
obesity, insulin resistance, blood pressure, and more.18   
Maternal and infant health are inexorably linked biologically, behaviorally, through the 
shared environment, and through breastfeeding.126,127 This link is particularly important in the 
context of HIV as the health of the mother and infant are fragile. In this context, the health of the 
mother and infant can be connected through several, unique mechanisms (Figure 4): 
1. HIV progression can induce weight loss through changes in diet, absorption, metabolism, 
and other factors.105 Even mild weight loss is associated with increased risk of death among 
HIV-positive individuals.106 Therefore, changes in weight are an important marker of health 
in this context. Weight loss in the postpartum period is normal, but most of this occurs in the 
first six months postpartum.107–109 Among HIV-positive women in sub-Saharan Africa, there is 
little change in BMI from six to 24 months postpartum.128 There is no difference in the rate of 
weight loss between HIV-positive and HIV-negative women in the first two years postpartum, 




disease progresses.129 These data indicate that failure to maintain viral suppression may be 
related to accelerated weight loss from six to 24 months postpartum. By meeting the 
combined energetic demands of lactation and combating the virus, maternal weight stability 
may support viral suppression. Although there is no association between maternal body 
mass index (BMI) and disease progression in sub-Saharan Africa,128 the effect of changes in 
weight remains unknown. It is likely that changes in weight status better reflect the dynamic 
process of disease progression than absolute weight. 
 
2. Maternal viral suppression will decrease infant exposure to HIV in utero and through 
breastmilk,130 thereby decreasing any negative biological effects of HIV exposure on infant 
growth. Viral suppression will also improve maternal health, decreasing the infant’s 
exposure to other HIV related opportunistic infections and improving the mother’s ability to 
care for the infant. Measures of maternal viral load and CD4+ are related to infant growth 
and health outcomes.101,102,131  
 
3. It is as yet unclear if HIV increases the energetic demands of breastfeeding; however, 
breastfeeding itself is known to require about 500 kilocalories a day.104 Women may 
mobilize their fat stores to meet these demands.104 Women in Malawi believe there is an 
interaction between nutrition, HIV-disease progression, and the ability or choice to 
breastfeed, especially in resource restricted settings.5 In this context, women with significant 
weight loss may choose not to breastfeed to preserve their own health. There is conflicting 
evidence regarding an association between breastfeeding and postpartum weight loss.132  
 
4. Breastfeeding supports infant growth, and rapidly growing infants may breastfeed more. 
Many studies have found relationships between breastfeeding and growth, but these 




36,133  A major limitation of these studies is the possibility for reverse causation. Women tend 
to adjust their breastfeeding status to cues from the infant and perceived infant health.134–137 
As such, it is possible that breastfeeding may affect infant growth and infant growth may 
affect breastfeeding decisions. 
 
5. The effect of maternal weight status on infant growth after birth remains unclear.110 In low 
resource settings, less weight loss may allow the mother to invest more in her child, 
improving infant growth, especially in the context of HIV. In Tanzania, low gestational mid-
upper arm circumference (MUAC) and HIV-exposure predict lower values in weight-for-age 
z-score (WAZ) and length-for-age z-score (LAZ), with infants experiencing both having the 
worst outcomes.111 In Malawi, daughters of women with low BMI who lost weight have less 
weight gain and decreased linear growth than daughters of women without these risk 
factors.112 In the context of HIV, accelerated weight loss could reflect increasing disease 
severity. As such, maternal weight loss could represent maternal depletion, increasing 
disease severity, or environmental hardships affecting both the mother and the infant. 
 
Here, we examine the relationship between viral suppression, maternal weight loss, 
breastfeeding, and infant linear growth in the first two years of life among HEU infants in urban 
Rwanda. By taking a longitudinal, structural equation modeling approach, we are able to 
understand the effects of these factors on one another over time. The longitudinal nature of this 
analysis is especially important as these factors may feedback on one another.  
Materials and methods 
The Kabeho Study (Kigali Antiretroviral and Breastfeeding Assessment for the 
Elimination of HIV) enrolled 608 HIV-positive, pregnant or postpartum women participating in 




facilities in Kigali, Rwanda. Enrollment in the Kabeho study took place from April 2013 to 
January 2014. All women were placed on lifelong antiretroviral therapy (Option B+). The 
majority of women received tenofovir, lamivudine, and efavirenz. In some cases, zidovudine 
replaced tenofovir or nevirapine replaced efavirenz. However, there is insufficient variation in 
ART regimen to examine variation in this variable. Women were required to have documented 
HIV infection, plan to remain in the Kigali area after delivery, and provide consent. Study visits 
were conducted at the health facilities within two weeks of birth; at six, 10, and 14 weeks; 
monthly from four to 18 months; and at 21 and 24 months. Attendants in the clinical settings 
measured birth weight where births took place. If recorded birth weight was not available, we 
used measurements taken at the Kabeho birth visit as a measure of neonatal weight. At each 
visit, trained nurses took duplicate measures of infant length to the nearest centimeter (cm) 
using Shorr boards, and weight to the nearest 10 grams using United Nations International 
Children’s Relief Fund scales. Maternal weight was measured at six, 12, 18, and 24 months. 
Viral load was measured at birth, 18 months, and 24 months. Viral load testing was conducted 
using the Roche Cobas Ampli-Prep/Cobas TaqMan HIV-1 quantitative test. The lower limit of 
detection for this test (20 copies/ml) was used to define viral suppression. At each visit, women 
were asked if they had experienced a food shortage in the last month and if they were currently 
breastfeeding. Women were asked if they had a caesarian delivery, which is a predictor of 
breastfeeding initiation in Rwanda. The date at which treatment was initiated was collected for 
all women.  
Maternal rate of weight change was calculated by subtracting the weight at the 
beginning of the period from the weight at the end and dividing by the number of months 
between measures. A factor score was developed for each facility that represented the level of 
training of staff in infant feeding counseling. This was a significant predictor of breastfeeding 
initiation in exploratory analysis. Because this is a facility level variable, data were clustered at 




the date at which ART was started from the birth date. This results in most values being 
negative, reflecting starting ART before infant birth. The median time since the initiation of ART 
was -1.55 years. Structural equation models were developed in MPLUS using full information 
maximum likelihood (FIML).138 Continuous variables were standardized to have a mean of zero 
and a standard deviation of one.  
Temporality was carefully considered in the development of the model. Viral suppression 
measures can be viewed as reflecting a longer period of suppression, which started several 
weeks or months before the measure. If this approach is adopted, current viral suppression 
could have already affected current infant length. Alternatively, viral suppression can be viewed 
as only reflecting current status and, therefore, only affecting future growth. Because many 
women initiated treatment near birth, we consider the viral load measure of the mother at the 
time of brith to reflect only current status and affect only future growth. However, more than 80% 
of women showed concordance in their viral status at 18 and 24 months, so these are 
considered to reflect a chronic state and to have already acted on infant growth by the time of 
measurement. Maternal weight change is assumed to have had enough time to influence infant 
growth by the end of the period. Breastfeeding status at the beginning of a period is assumed to 
affect weight change throughout the subsequent period. A reciprocal relationship between 
breastfeeding at the end of a period and weight change throughout the period is modeled as 
maternal depletion could cause breastfeeding cessation. All values are expected to influence 
their own subsequent values.  
Maternal education, age, and height; time since the initiation of ART; staff trained in 
infant feeding; delivery method; neonatal WAZ; food shortages; and infant sex are included in 
the model as controls and for identification. CD4 was not examined as viral load was the 
preferred measure of disease severity. The model was originally estimated with size outcomes 
at three, 12, 18, 21, and 24 months. However, the 12 and 21 month time points were dropped 




ratio of children to adults in the household, dietary diversity, meal frequency, and illness 
episodes were included in the original model but removed due to poor model fit. Breastfeeding 
at 24 months was dropped from the model due to limited variation; 97% of infants were already 
weaned.  
Results 
A final sample of 502 infants had sufficient data to be included in analysis. Descriptive 
statistics are reported in table 8. Average maternal weight change was minimal from six to 24 
months. There was no significant difference in weight change by food security or viral 
suppression status. In univariate analysis, weight change from six to 12 and 18 to 24 months 
was inversely related to weight at the beginning of each period (p-values<0.04). Mean maternal 
BMI was approximately 23 at all time periods. At baseline, nearly all infants were breastfed 
(94%) and most were weaned by 18 months (80%). Infants whose mothers reported a food 
shortage in the previous month were more likely to be breastfed at 18 months (p-value<0.001). 
More than 25% of women reported a food shortage in the month proceeding each visit, with this 
value reaching almost 40% at the three month visit. Average LAZ declined from -0.83 at three 
months to -1.69 by 24 months.  
The final model estimated is illustrated in figure 5 (Table 9). Only coefficients with p-
values less than 0.05 are represented in the figure. The root mean square error of 
approximation (RMSEA) was 0.01. The standardized root mean square residual (SRMR) was 
0.08. The comparative fit index (CFI) was 0.97. These values indicate adequate model fit.  
Older mothers are more likely to be virally suppressed and to breastfeed (Table 9, 
Figure 5). Viral suppression and the mother being on ART for longer are related to lower infant 
LAZ at three months. A more positive maternal weight change is related to higher infant LAZ at 
the end of each period. At 12 months, a higher infant LAZ is related to increased probability of 




related to higher LAZ. Generally, values among repeated measures predicted subsequent 
values. 
Discussion 
All model fit indexes demonstrate that our structural equation model accurately fits the 
data and describes the sample. Among this cohort of HIV infected mothers and HEU infants in 
Kigali, Rwanda, we found persistence in viral suppression, food shortages, breastfeeding status, 
and infant LAZ; the values at one period are positively related to the values at the following 
period. Weight change from 12 to 18 months is related to the inverse change in the subsequent 
period, reflecting stable maternal weight. The relationships of the repeated measures over time 
are both logical and intuitive, indicating that the model is well specified.  
More positive maternal weight change is related to higher infant LAZ at the end of the 
period. However, the pathways between weight change and LAZ function independently of 
breastfeeding as this was accounted for in the earlier periods and few infants were still 
breastfed later. Given that the pathway is not through breastfeeding and the relatively high 
mean maternal BMI, it is unlikely that this relationship is the result of maternal depletion leading 
to the mother being unable to care for her infant. At six months, 10 women had BMIs less than 
18. At 18 months, 12 women had BMIs less than 18. Because of the lack of a relationship 
between viral suppression and weight change in univariate or multivariate analysis, it is unlikely 
that weight change represents a measure of disease severity in our sample. Furthermore, 
because food security and maternal weight change are not related in univariate analysis or this 
structural equation model and maternal education does not affect infant LAZ, maternal weight 
change is unlikely to be acting as a measure of socioeconomic status. As such, we conclude 
that maternal weight change must reflect some other environmental factor that supports both 
infant and maternal wellbeing. Future research should attempt to identify this protective factor. 
Older women are more likely to be virally suppressed and to breastfeed. There is little 




ages of 18-30 and 30-40 in South Africa, indicating little difference in disease progression.139 In 
the United States and Canada older individuals are more likely to achieve viral suppression.140 
This may be because older individuals have better adherence.141 We were unable to consider 
adherence because most of our participants reported perfect adherence. The association 
between maternal age and breastfeeding is well established. In Tanzania, older mothers are 
more likely to exclusively breastfeed for six months.142 Younger Kenyan mothers experience 
more barriers to breastfeeding than older women.143 Such barriers include poor body image, 
school, and poverty. In Malaysia, maternal parity, which is associated with age, is related to 
exclusive breastfeeding.144 Similarly in India, maternal parity is related to a score of 
breastfeeding behaviors.145  
Women who initiated ART more recently have infants with higher LAZ at three months. 
These women could be earlier in the disease and healthier as they likely were diagnosed 
through routine screening at the antenatal care unit rather than after attending the clinic due to 
illness. The effect of exposure to ART on infant growth is unknown, but certain drugs may be 
associated with infant size.10,12,63,64 Infants whose mothers started treatment more recently may 
have less exposure to ART and, therefore, better early growth. This could also explain the 
negative association between maternal viral suppression and early LAZ. Women with more 
medication in their bodies are more likely to be suppressed, their infants are exposed to more of 
the treatment, and the drug has a larger, negative effect on growth.  
The negative effect of ART on LAZ is supported by the lack of a relationship between 
viral suppression and growth at 18 and 24 months when infants are likely to have already been 
weaned and, therefore, would not be exposed to ART though breastmilk. However, at 18 
months, breastfeeding is related to decreased linear growth, possibly because continued 
exposure to ART is harmful. These relationships indicate that the effect of ART on growth may 
be temporary as they appear to dissipate when infants are no longer exposed. However, 




foods. These infants have lower dietary diversity and meal frequency. They are less likely to 
receive animal or soy milk, juice, dairy, or fruit than infants who are no longer breastfeeding.  
Pervious work in sub-Saharan Africa also found that breastfed infants ages 12 to 18 
months are shorter and lighter than their weaned counterparts.146 However, this study was 
unable to determine the directionality of causation. We see that, at 12 months, taller infants are 
more likely to still be breastfed and, at 18 months, breastfed infants tend to be shorter. This 
indicates the possibility of a two-way, time varying relationship that should be investigated 
further in future research. 
The reason for a positive relationship between food shortages and LAZ at 18 months 
remains unclear. Although non-significant in the model, infants who experience food shortages 
at 18 months are more likely to still be breastfed than those who do not. This is likely because 
women experiencing extreme poverty will give their children any food available, including that 
which their own bodies produce. For example, in Haiti, extreme food insecurity was associated 
with increased length of exclusive breastfeeding as a “last resort.”147 The same altered dietary 
pattern associated with continued breastfeeding is associated with food shortages in our 
sample. Food shortages are also associated with lower maternal height and education. 
Therefore, the relationship between food shortages and LAZ must be considered in the context 
of the complete model and other sources of variation. In univariate analysis, food shortages at 
18 months are related to decreased LAZ (coefficient = -0.41, p-value = 0.003); however, in 
multivariate linear regressions, this effect becomes non-significantly positive. As such, the 
relationship between food security and LAZ at this age likely reflects a complex interaction 
between this variable and the others in the model. It should not be interpreted as causal. 
This study has several limitations. First, structural equation modeling is often used as an 
explicitly causal framework. There are, therefore, some concerns about using structural 
equation modeling in the context of a purely observational study. However, there is no need to 




from doing so. Second, we only have three viral load measures. More measures would have 
allowed us to examine potential effects of viral load throughout the life course in more detail. 
Third, our sample has some loss to follow-up. The final model included data from 502 infants, 
but not all of these infants had observations in all time periods. The use of FIML allows infants 
to contribute partial data and does not drop infants with some missing data. Nonetheless, 59 
(12%) infants were dropped due to excessive missingness. However, we have no reason to 
believe that the mechanisms reflected in our structural equation model would function differently 
within the subgroup of infants who were lost to follow-up. Finally, this is a relatively small sample 
size for a complex structural equation model. As such, we cannot conclude that any of the null 
relationships truly do not exist within our population. We may not have the power to identify all 
true associations. 
Conclusions 
This work demonstrates the relationship between maternal and infant health in the 
context of HIV. Time on ART and viral suppression are related to decreased early infant LAZ. 
The effect of exposure to HIV and ART in breastmilk may persist as long as the infant is 
exposed but may then fade. Maternal weight change is positively correlated with infant LAZ. 
This supports the ongoing shift in the public health approach to postpartum care that prioritizes 
the wellbeing of the mother-infant dyad rather than considering each separately. Additional work 
is needed to understand how the mother and infant influence one another and how their health 









Table 8: Descriptive characteristics of sample over time 
 
  Baseline  18 months  24 months 
    N / mean % / SD1   N / mean % / SD   N / mean % / SD 
Total N2 561   473   389  
Female N2 289 52%  243 51%  200 51% 
Neonatal WAZ -0.76 126%       
Mother completed primary school 245 44%       
Maternal Viral load         
 <10 316 56% 
 336 78%  334 78% 
 >10 246 44% 
 96 22%  93 22% 
LAZ4 -0.83 1.11  -1.53 1.12  -1.56 1.03 
Rate of maternal weight change over 
proceeding six mo. (kg)3 
   0.08 0.67  0.03 0.61 
Breasfed4 508 94%  94 20%  15 3% 
Reported infant morbidity4 89 17%  229 47%  196 43% 
Infants with dietary diversity > 3    371 82%  335 84% 
Infants with meal frequency > 4    284 63%  206 52% 
Reported household food shortage4 209 39%   96 27%   163 36% 
1. Standard deviation 
2. Number of infants with LAZ measurements 
3. Months 




Table 9: Coefficients for each relationship in the estimated structural equation model 
Acted upon variable Acting variable Coeff1 SE2 P-value 
Virally suppressed 
at birth 
Time since the initiation of ART 0.123 0.063 0.051 
Maternal age 0.1663 0.066 0.012 
Maternal age2 -0.032 0.066 0.628 
Mother attended secondary school 0.010 0.145 0.942 
Breastfeeding at 3 
mo.4  
Time since the initiation of ART 0.045 0.052 0.385 
Maternal age 0.390 0.071 <0.001 
Maternal age2 -0.320 0.058 <0.001 
Mother attended secondary school -0.008 0.131 0.949 
Neonatal WAZ -0.011 0.062 0.861 
Food shortage at 3 mo.  0.07 0.082 0.391 
Virally suppressed at birth 0.079 0.09 0.377 
LAZ at 3 mo. 0.202 0.412 0.624 
Staff trained in infant feeding counseling 0.16 0.081 0.049 
Planned caesarian delivery -0.076 0.118 0.523 
LAZ at 3 mo.  
Time since the initiation of ART 0.105 0.04 0.009 
Maternal age 0.119 0.160 0.460 
Maternal age2 0.005 0.127 0.966 
Mother attended secondary school 0.075 0.076 0.322 
Neonatal WAZ -0.020 0.051 0.697 
Food shortage at 3 mo.  -0.091 0.097 0.350 
Virally suppressed at birth -0.164 0.062 0.008 
Maternal height -0.032 0.050 0.523 
Breastfeeding at 3 mo.  -0.524 0.591 0.376 
Infant sex 0.179 0.141 0.203 
Breastfeeding at 6 
mo.  
Breastfeeding at 3 mo.  3.674 4.356 0.399 
LAZ at 6 mo.  0.495 0.610 0.418 
Food shortage at 6 mo.  0.01 0.135 0.939 
LAZ at 6 mo.  
LAZ at 3 mo. 0.910 0.036 <0.001 
Breastfeeding at 6 mo. -0.046 0.052 0.369 
Food shortage at 12 mo.  -0.009 0.050 0.861 
Food shortage at 6 
mo.  Food shortage at 3 mo.  1.282 0.072 <0.001 
Maternal weight 
change from 6 to 12 
mo.  
Virally suppressed at birth -0.074 0.061 0.226 
Breastfeeding at 6 mo. 0.06 0.120 0.621 
Breastfeeding at 12 mo.  -0.336 0.337 0.318 
Food shortage at 6 mo.  0.098 0.081 0.228 
Breastfeeding at 12 
mo.  
Breastfeeding at 6 mo. 0.379 0.409 0.354 
LAZ at 12 mo.  0.247 0.064 <0.001 
Food shortage at 12 mo.  0.110 0.065 0.093 
Maternal weight change from 6-12 mo.  0.316 0.274 0.248 




Food shortage at 12 mo.  0.054 0.052 0.300 
Maternal weight change from 6-12 mo.  0.098 0.046 0.035 
Food shortage at 12 
mo.  Food shortage at 6 mo.  0.849 0.139 <0.001 
Maternal weight 
change from 12 to 
18 mo.  
Virally suppressed at birth -0.125 0.132 0.345 
Maternal weight change from 6-12 mo.  -0.656 0.410 0.110 
Breastfeeding at 12 mo.  0.484 0.277 0.080 
Breastfeeding at 18 mo.  -2.92 2.686 0.277 
Food shortage at 12 mo.  0.189 0.168 0.260 
Breastfeeding at 18 
mo.  
Breastfeeding at 12 mo.  0.232 0.108 0.031 
LAZ at 18 mo. -0.08 0.051 0.112 
Food shortage at 18 mo.  0.031 0.056 0.575 
Maternal weight change from 12-18 mo.  0.911 0.142 <0.001 
Virally suppressed at 18 mo.  -0.046 0.109 0.674 
LAZ at 18 mo.  
LAZ at 12 mo. 0.875 0.028 <0.001 
Breastfeeding at 18 mo.  -0.231 0.110 0.036 
Food shortage at 18 mo.  0.122 0.043 0.004 
Maternal weight change from 12-18 mo.  -0.052 0.045 0.251 
Virally suppressed at 18 mo.  -0.015 0.051 0.765 
Food shortage at 18 
mo.  Food shortage at 12 mo.  0.771 0.124 <0.001 
Virally suppressed 
at 18 mo.  
Virally suppressed at birth 0.557 0.166 0.001 
Maternal weight change from 12-18 mo.  -0.106 0.130 0.413 
Maternal weight 
change from 18 to 
24 mo.  
Virally suppressed at 18 mo.  -0.036 0.068 0.595 
Maternal weight change from 12-18 mo.  -0.224 0.048 <0.001 
Food shortage at 18 mo.  0.015 0.04 0.704 
LAZ at 24 mo.  
LAZ at 18 mo. 0.817 0.027 <0.001 
Food shortage at 18 mo.  0.039 0.131 0.767 
Maternal weight change from 18-24 mo.  0.111 0.034 0.001 
Virally suppressed at 24 mo.  -0.032 0.038 0.398 
Virally suppressed 
at 24 mo.  
Virally suppressed at 24 mo.  0.838 0.114 <0.001 
Maternal weight change from 18-24 mo.  -0.111 0.088 0.204 
Food shortage at 24 
mo. Food shortage at 18 mo.  0.104 0.096 0.275 
1. Coefficient 
2. Standard error 














Figure 4: Theoretical framework demonstrating the relationship between viral 








All effects reported have p-values less than 0.05. See table 9 for information regarding coefficients, standard errors, and p-values.
Figure 5: Structural equation model of the relationship between viral suppression, maternal weight change, 
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CHAPTER 5: INFLAMMATROY BURDEN RELATES TO FUTURE GROWTH AMONG HIV-
EXPOSED AND –UNINFECTED INFANTS IN THE BAN TRIAL IN MALAWI  
 
Summary 
Background: HIV-exposed and –uninfected infants have a different pattern of immune 
development than their unexposed counterparts. With the growing awareness that immune 
activation in the absence of overt illness can have negative health consequences, it is 
necessary to investigate the effect of inflammation on growth in this subpopulation.  
Methods: Inflammatory markers were measured in 335 infants from Lilongwe, Malawi at 
two weeks and 484 infants at 24 weeks. Approximately half of their mothers were randomized to 
receive lipid nutrient supplements. A latent variable reflecting total inflammatory burden, as 
measured by C-reactive protein (CRP), alpha-1-acid glycoprotein (AGP), and neutrophil count, 
was developed at two and 24 weeks. The relationship between this value and growth over the 
following four weeks was examined through the use of four linear regressions, which considered 
different time frames and possible mechanistic actions.  
Results: Higher inflammatory burden at 24 weeks relates to slower weight gain among 
infants whose mothers were not supplemented, but this is reversed among infants whose 
mothers were supplemented. Inflammation at two and 24 weeks relates to linear growth, with 
interactions between ponderal index, maternal treatment, and inflammation. If an infant recently 
experienced illness, a higher inflammatory burden is related to faster, early linear growth. 
Conclusion: We demonstrate the interaction between inflammation, maternal 
supplementation, and growth. The effects of inflammation on growth may be chronic. 







HIV-exposed and -uninfected (HEU) infants have a different pattern of immune 
development than unexposed infants.82,83,148 For example, HEU infants in Zimbabwe have 
higher levels of C-reactive protein (CRP) than unexposed infants at six weeks and six months of 
age.84 Some studies have raised concern about the effects of maternal antiretroviral 
medications on infant immune responses.13,88 In Malawi, prophylactic cotrimoxazole but not 
antiretroviral treatment (ART) is related to neutropenia.86,87 Increasing evidence links 
inflammation and infant growth, indicating that these changes may have broad consequences.  
Early inflammation is related to a variety of poor growth outcomes. In rural Zambia, 
serum alpha-1-acid glycoprotein (AGP) is negatively related to rate of linear growth after 
controlling for dietary intake and maternal height.149 In a study in Tanzania, systemic 
inflammation, measured by elevated CRP or AGP, was related to increased stunting at six 
weeks.150 Similarly, a case-control study in Zimbabwe found that infants who are stunted at 18 
months had higher levels of CRP and AGP throughout infancy.151 Among a group of Bolivian 
children ages two to four years, elevated CRP is related to decreased linear growth over the 
subsequent three months, with this effect being particularly pronounced in infants with skinfold 
thickness below the median.152 However, a study of Bolivian infants ages two to 18 months 
found no effect of elevated CRP, AGP, or a combined score on odds of stunting or being 
overweight.153 Among other factors, these results are likely affected by the variety of 
approaches used to account for the effect of illness on both inflammation and growth. Such 
approaches include not addressing the issue,151,152,154 excluding sick infants,155 controlling for 
reported illness150,153 or antibiotic use,156 and investigating the interaction between illnesses and 
inflammation.149  
Given the uncertainty of the effect of inflammation on growth among the general 
population, it is not surprising that the effect of inflammation on growth among HEU infants 





viral exposure may alter the relationship between inflammation and growth. Decreased growth 
associated with inflammation could be due to the direct action of the inflammatory markers, their 
upstream regulators, or the environmental conditions inducing inflammation. We hypothesize 
that infants with higher inflammatory burdens in the absence of overt illness will have slower 
growth. We further expect the effect of maternal and infant antiretroviral medication and 
maternal nutritional supplementation to modulate the relationship between inflammation and 
growth. A strength of our research is that we are able to exclude sick infants, control for recent 
illness, and investigate the interaction between illness and inflammation. 
Methods 
Participants 
The Breastfeeding, Antiretroviral, and Nutrition study (BAN) was a randomized controlled 
trial of 2,373 mother-infant pairs conducted in Lilongwe, Malawi from April 2004 to February 
2010.87,115  BAN investigated the effectiveness of ART provided to mothers or infants in 
preventing mother-to-child transmission of HIV during breastfeeding. BAN also evaluated the 
effects of a maternal nutrition supplement during lactation to support maternal health. As such, 
half of the mothers received a daily lipid-based nutritional supplement (LNS, Nutriset, Malaunay, 
France) that met the estimated added energy (700 kcal) and protein (20 g) requirements of 
lactation and provided the recommended daily allowance of most micronutrients. Within the LNS 
groups, mother-infant pairs were randomized to maternal ART, infant ART, or no ART. After 
March 2008, assignment to the no treatment groups was discontinued, and women who were 
still breastfeeding were offered maternal or infant drug regimens.115 Intensive exclusive 
breastfeeding counseling was provided to mothers in accordance with World Health 
Organization (WHO) guidelines at the time.96,115 Mothers were instructed to exclusively 
breastfeed for 24 weeks, then to stop breastfeeding between 24 and 28 weeks.157 Study visits 
were scheduled at 1, 2, 4, 6, 8, 12, 18, 21, 24, 28, 36, 42, and 48 weeks, with selected visits 





cotrimoxazole (240 mg, once daily, from 6 to 36 weeks) was given to all infants for prevention of 
malaria and opportunistic infections according to Malawi Ministry of Health and Population and 
WHO guidelines.158,159 There were meaningfully different environmental conditions before and 
after 2006, with a severe drought happening in the earlier portion of the study. Therefore, it is 
not possible to isolate the effect of prophylactic cotrimoxazole from that of the drought.     
The Malawi Mothers and Infants Study (MaMI) selected a subsample of BAN 
participants for detailed analysis of micronutrient and inflammation biomarkers in stored plasma 
samples. Because of MaMI’s nutrition focus, the sub-study aimed for equal numbers from the 
maternal LNS and no LNS groups, and prioritized samples from infants with concurrent 
anthropometry and dietary data. We excluded multiple births (n=49) and infants who became 
HIV-infected (n=58). There were 335 infants with laboratory measurements at two weeks and 
489 at 24 weeks; 49% of infants had samples at both periods. Baseline characteristics are 
similar across periods; therefore, infants are expected to be comparable (Table 10). Informed 
consent was obtained from all participating mothers. The Malawi National Health Science 
Research Committee and the institutional review boards at University of North Carolina at 
Chapel Hill, University of California, Davis, and the U.S. Centers for Disease Control and 
Prevention approved the study. 
Inflammatory markers 
Because inflammation is a multi-faceted biological concept, measures of inflammation 
are sometimes combined into scoring metrics.150,153,154 Such scores may better capture the total 
effect of inflammation than the use of individual metrics. They reduce problems associated with 
multiple testing and the collinearity of measures. We develop a latent score measuring 
inflammatory burden among MaMI infants through four markers: CRP, AGP, neutrophil count, 
and the ratio of ferritin to transferrin (TRF). These four markers reflect four different aspects of 





metric could. The physiological functioning of these markers is reviewed in supplemental 
materials one. 
Plasma biomarker analyses were completed at the United States Department of 
Agriculture Western Human Nutrition Center in Davis, CA. High sensitivity CRP, AGP and 
transferrin receptor concentrations were measured using immunoturbidimetic assays on the 
Cobas Integra 400 analyzer (Roche Diagnostics, Indianapolis, IN). Ferritin was measured with 
IRMA Ferritin Coat, a Count radioimmunoassay (Siemens Health Care Diagnostics Inc., 
Plainfield, IN). Neutrophils were measured in Malawi as part of a complete blood count.   
Infant morbidity 
At each visit, physicians conducted infant physical examinations, noting the presence or 
absence of specific conditions from a checklist that included rash, oral thrush, herpes, otitis 
media, cough and other pneumonia-related symptoms, and results of palpation of the liver, and 
spleen. Physicians also recorded, other infant symptoms, including body temperature. Mothers 
reported whether, since the last clinic visit, their infants had specific symptoms read from a 
checklist that included fever, abdominal pain, vomiting, diarrhea, rash, cough, shortness of 
breath, yellow eyes, weakness, failure to suckle, oral sores, swollen glands, seizures, and 
“other.”  
To distinguish the effect of inflammation from the effect of illness, infants with an ongoing 
infectious illness at the time of the inflammatory measure are excluded from analysis. Physician 
diagnosis is the basis for this exclusion because it reflects infant status at the time of the blood 
draw used for the biomarker assays. Infants with an ongoing illness are expected to have 
altered inflammatory profiles that do not reflect the common inflammatory profile of the 
population. Therefore, they are inappropriate for inclusion in the estimation of a latent variable 
reflecting population wide patterns in inflammation. Furthermore, illness itself can affect growth, 
making it a confounder in the path between growth and inflammation. Although infants who 





longer-term changes are of interest. They are more likely to be present in the entire population 
and to be more chronic. Also, the direct effect of the illness on growth is expected to have 
already occurred, making it no longer a confounder. The number of infants excluded due to 
illness at each time period is reported in table 10. 
Anthropometry 
At each visit, weight was measured using Tanita digital infant scales; and length was 
measured with length boards made to United Nations International Children’s Emergency Relief 
Fund specifications. Weight-for-length and length-for-age z-scores were calculated using the 
WHO Growth Reference.160160  
Analysis 
Latent scores of inflammatory burden were developed independently at two and 24 
weeks based on CRP, AGP, neutrophil count, and the ratio of ferritin to transferrin. Scores were 
calculated separately at each time point because inflammatory profiles change as infants’ 
immune systems develop. The development of inflammatory burden scores was conducted in 
MPLUS using full information maximum likelihood (FIML). All data were standardized to have a 
mean of zero and a standard deviation of one so that the scales across measurements were 
similar. Data were not log transformed despite being skewed in order to maintain the inherently 
skewed nature of inflammatory burden, which has meaningful biological implications. Mixture 
modeling was considered to allow for the latent variable to include latent classes with shifted 
underlying distributions of inflammation to support the skewed distribution; however, when no 
latent classes were identified, these were dropped from the model. Since the ratio of ferritin to 
transferrin did not significantly weight onto either measure of inflammatory burden, indicating a 






The relationship between inflammatory burden and length-for-age z-score (LAZ) and 
weight-for-length z-score (WLZ) four weeks after the measure was estimated in a series of 
linear regressions controlling for z-score at the time of the inflammation measure, termed 
baseline anthropometry. This approach allows for an investigation of the effect of inflammation 
on growth, rather than size. A four week time horizon was chosen to allow sufficient time for 
inflammation to have acted on growth. Over a longer time period, infants may recover from 
growth setbacks caused by inflammation. We assume that baseline inflammation is related to 
inflammation over the following four week period. Plots of the residuals vs. fitted values and QQ 
plots were inspected to check for normality assumptions.  
In our context, we expect that inflammation is affected by four primary factors: current 
illness, adiposity, ART exposure, and recent illness. By accounting for these factors, we 
attribute the relationship between inflammatory burden and growth to chronic, asymptomatic 
disease and/or HIV-exposure rather than these other causes. Infants with current illness are 
dropped from the sample, so any relationships identified will not be driven by the ongoing 
infection. Adiposity is controlled for in models where it is not the outcome. ART is controlled for 
in all models. Recent illness is examined in one of the following four models which we develop.  
First, we establish the relationship between inflammatory burden score and growth in 
LAZ and WLZ controlling for infant sex; weeks between visits; maternal education, age, and 
height; birth year; and study arm. BAN study arm is reflected through the use of two variables: a 
maternal ART, infant ART, or no treatment variable and a binary variable reflecting if the mother 
received LNS. Because some inflammatory markers are produced in adipose tissue, ponderal 
index (kilograms divided by meters cubed) at the time of the blood draw is included in the 
models that consider LAZ. Ponderal index (PI) is a measure of adiposity that is not highly 
correlated with length. PI is not controlled for in the models considering WLZ because adiposity 
is represented in the dependent variable. Infant sex; weeks between visits; maternal education, 





interaction was individually added to, then removed from the model and Bayesian information 
criteria (BIC) values were compared. Similarly, alternate functional forms were examined by 
adding an inflammation squared term. These alternate model specifications did not improve 
model fit and are not presented. Model one estimates the overall relationship between 
inflammation at two or 24 weeks and growth over the following four weeks after controlling for 
the above factors.  
Then, we introduce interaction terms to the baseline model. We interact inflammatory 
burden with treatment arm to determine if the relationship between inflammation and growth is 
altered by treatment. We further interact inflammation with PI to reflect the possibility that 
inflammation may have disproportionally negative impacts on children with smaller energy 
reserves.152 
Next, baseline anthropometry is dropped from the model. If prior inflammation affects 
current size and prior inflammation is highly correlated with current inflammation, baseline 
anthropometry becomes a mediator, rather than confounder, between a chronic state of 
inflammation and future growth. However, without baseline anthropometry in the regression, this 
model considers size, not growth. Therefore, this model tests the null hypothesis that 
inflammation is not related to future size. By comparing results of this model to those of the 
previous model, we are able to determine which relationships between inflammation and growth 
are due to a chronic state or an acute state. Any relationship that is identified in this model but 
not seen in the previous one must be due to a chronic state of inflammation acting both on 
baseline and future size.    
Finally, because a recent illness could have residual effects on inflammation, maternal 
report of an illness since the last study visit is added to the model. Infants experiencing an 
ongoing illness are already excluded; however, infants with a recent illness could have 
continuing, residual elevations in inflammation that affect the relationship between inflammation 





longer-term effects of illness after recovery. Here, we examine the effect of recent illness in 
modulating the relationship between inflammation and growth. 
Results 
Participants are roughly equally distributed across the three treatment and two 
supplement arms (Table 10). All baseline characteristics are similar among infants with data at 
two weeks but not 24 weeks, 24 weeks but not two weeks, and measures at both periods. Mean 
LAZ decreases slightly, but WLZ increases considerably. PI is negatively correlated with LAZ 
and positively correlated with WLZ at both periods (p-values<0.001). There is no association 
between PI and inflammatory burden at either period (p-values>0.40).   
Early (two weeks) inflammatory burden measures are heavily driven by CRP; however, 
later (24 weeks) the three measures of inflammatory burden weight approximately equally onto 
the score (Table 11). Despite having been transformed, inflammatory burden and its normalized 
values remain highly skewed (Figure 6). In both periods, CRP, AGP, and neutrophil count are 
significantly correlated with the calculated inflammatory burden score, indicating that the latent 
variable is suitable (Table 12). In most cases, these measures are also significantly correlated 
with one another. There is low correlation of measures across time periods. Post hoc Kruskal-
Wallis tests were used to determine if inflammation varied by study arm. There is no difference 
in inflammatory burden by drug regimen; however, at 24 weeks, infants whose mothers received 
LNS have lower inflammatory burden scores than those without supplementation (p-value=0.04, 
Figure 7).  
Model one examines the relationship between our inflammatory burden score at two and 
24 weeks and growth in LAZ (Table 13) and WLZ (Table 14) over the following four weeks. 
Inflammation is not significantly related to either growth outcome at either time. Birth year is 
related to slower early linear growth. Taller maternal height is associated with faster linear 






Model two considers possible modification of the effect of inflammation on growth by 
treatment arm. Higher inflammatory burden at 24 weeks is related to slower weight gain among 
infants whose mothers were not supplemented, but this effect is reversed among infants whose 
mothers received supplementation (Figure 8). Furthermore, while none of the individual 
interaction terms reaches statistical significance for LAZ at this time, the F-test indicates that 
inflammation is related to linear growth. Increasing PI and inflammatory burden interact to 
produce the tallest infants.  
In the next model, model three, baseline anthropometry is removed to estimate the 
chronic effect of inflammation on size under the assumption that our inflammatory marker 
represents inflammation not only at the time of the blood draw, but also previously. Here, a 
much stronger effect of maternal supplementation is seen, with infants of supplemented 
mothers being shorter early in life (Figure 9). The relationship between inflammation and LAZ is 
modified by maternal supplementation and PI.  
Finally, in model four, we considered the effect of recent illness. Recent illness is related 
to slower linear growth and accelerated relative weight gain. The main effect of inflammatory 
burden is related to decreased linear growth and accelerated relative weigh gain from two to six 
weeks. Infants with higher PI and no supplementation tend to have the fastest early linear 
growth, regardless of inflammatory burden, so long as they have not experienced a recent 
illness (Figure 10). However, if an infant has experienced a recent illness, a higher inflammatory 
burden is related to faster, early linear growth. Higher inflammation is also related to slower 
relative weight gain among these infants. At 24 weeks, low inflammation, maternal 
supplementation, and the absence of recent illness interact to be related to the slow relative 
weight gain. Low inflammation, no maternal supplementation, and recent illness are related to 
fast relative weight gain. At 24 weeks, infants with mother-reported illness since the last visit 
have higher median inflammatory burden than those whose mothers did not report illness 





Discussion     
We use CRP, AGP, and neutrophil count to construct latent variables reflecting the 
extent to which infants experience inflammation at two and 24 weeks. The latent variable and its 
measures are highly correlated. As such, they likely reflect the same underlying biological 
process.  
Our models indicate that the relationship between inflammation and growth among HEU 
infants is modulated by maternal supplementation and, to a lesser extent, ART. However, our 
simplest model, model one, did not find a relationship between inflammation at either time point 
or study arm and growth over the following four weeks. Similarly, previous work within the BAN 
study did not find a difference in growth outcomes by ART or LNS supplementation.15,59 
Nonetheless, model two demonstrates that maternal supplementation and ART may alter the 
relationship between inflammation on growth, thereby obscuring the true association. In 
particular, figure 8 shows lower inflammatory burden and maternal supplementation interact to 
be related to decreased WLZ at 28 weeks. These factors further interact with PI to predict LAZ 
at 28 weeks. An infant with low inflammation, high PI, and no maternal supplementation is 
expected to be taller than a similar infant with high inflammation. Maternal supplementation may 
alter the inflammatory profile of the mother and, thereby, the cytokines that the infant is exposed 
to through breastmilk. We therefore conclude that low inflammation and maternal 
supplementation combine to be related to lower relative weight gain and can interact with PI to 
be further related to accelerated linear growth. This is especially important as there is growing 
evidence that HEU infants may experience a growth pattern characterized by the exact 
opposite: accelerated relative weight gain and slow linear growth.14–16  
In model three, by removing baseline LAZ and WLZ, we do not account for the effects 
that our variables of interest may have had on size before our period of study. As such, any 
effect of our variables of interest on baseline values which also affect future outcomes is directly 





supplementation on size in model three than model two. Maternal supplementation is expected 
to affect both baseline and future size. Here, the effect which is mediated through baseline size 
is now directly attributed to the maternal supplementation variable. Assuming that inflammation 
at baseline reflects a chronic state, this model allows for the relationship between the chronic 
state of inflammation and size to be estimated without removing the effect which is mediated 
through baseline size. We see that inflammation has a chronic effect on LAZ, especially among 
infants whose mothers were not supplemented. Among these infants, lower inflammation is 
related to markedly higher length-for-age. Because this relationship is not seen when baseline 
LAZ is accounted for, we assume that the effect acts through baseline LAZ. As such, this 
demonstrates the chronic effect of inflammation on length.   
Finally, in model four, we show that inflammation in the context of a recent illness is 
related to faster early linear growth than if the infant had been sick but did not have a strong 
inflammatory response. In the absence of a recent illness, higher inflammation is related to 
slower linear growth. Recent illness, maternal supplementation, and inflammation interact to 
predict strikingly different patterns in relative weight gain at both periods. The effect of 
inflammation on linear growth is altered by recent history of illness and adipose reserves as 
well, as indicated by the interaction terms. Not all inflammation is harmful, and, in the proper 
context, inflammation can be a sign of normal and healthy development.  
Future work will need to investigate the longitudinal development of a healthy 
inflammatory response in HEU infants. We do not have sufficient repeated measures to map out 
the longitudinal development of inflammatory responses. As such, we are not able to fully 
disentangle chronic from acute inflammatory effects. A deeper understanding of the healthy 
development of infant inflammatory profiles is needed for the further investigation of the 
relationship between inflammation and growth in individuals without acute morbidities.   
This analysis does not consider the effect of medications on either inflammatory 





a result, they likely received significantly more medication than is the norm for infants in Malawi. 
The vast majority of these medications have the potential to influence the infant’s immune 
profile. The most commonly prescribed single medication was paracetamol, and the effects of 
paracetamol on inflammation remain unknown.161161 The most commonly prescribed class of 
medication was antibiotics. Nearly 85% of infants who were born before the introduction of 
prophylactic cotrimoxazole received cotrimoxazole as an antibiotic at one point. However, we 
could not account for confounding by indication, medications received offsite, or underlying 
patterns in health seeking behavior. Consequently, an investigation of the effects of medication 
on growth outcomes and inflammation is beyond the scope of this study.  
Conclusions 
We demonstrate an interaction between inflammation, maternal supplementation, ART, 
and infant growth. The effects of inflammation on growth may be chronic. Furthermore, its effect 
may be altered by the underlying cause of inflammation: recent illness or other factors. The 
effect of inflammation on growth is likely to be highly variable, depending on infant age, other 
biological stressors, and the time frame considered; but, that does not mean that it does not 
exist or can be ignored. Future work should attempt to establish the normal development of an 
HEU infant immune response and relate this to growth taking a longitudinal approach. Such a 
longitudinal approach may be better able to establish a single, long-term effect of inflammation 







Table 10: Description of sample 
Baseline characteristics             
Full sample 
 
Data available at 
both periods 
P-value1 
    N / mean % / SD2   N / mean % / SD 




Maternal height (cm) 156.71 5.41 
 
156.37 5.27 0.24 
Maternal age (year) 26.46 5.16 
 
26.44 5.15 0.70 




180 66% 0.28 
Female 258 47% 
 
136 50% 0.21 
Exclusively breastfed at 
24 weeks 





191 70% 0.07 
Received LNS 285 52% 
 
141 52% 0.78 
Treatment 
      
 
Maternal 180 33% 
 
87 32% 0.72  
Infant 218 39% 
 
103 38% 
  None 155 28% 
 
81 30% 
Evolving traits   
Two weeks 
 
Twenty four weeks 
    N / 
median  





% / interquartile 
range  
Included sample 335 NA 
 
489 NA 
Age (days) 14.00 1.00 
 
169.00 3.00 
Neutrophil count 2.00 1.25 
 
1.80 1.10 
Ferretin : TRF 122.69 139.26 
 
2.76 4.29 
CRP 0.45 1.18 
 
1.40 4.86 
AGP 0.43 0.31 
 
0.94 0.54 
LAZ -0.65 1.58 
 
-0.80 1.48 
WLZ -0.48 1.40 
 
0.20 1.47 
Excluded due to current illness3 
    
 
Fever 13 4% 
 
30 6%  
Diarrhea 0 0% 
 
23 5% 
  Cough 37 10%   75 13% 
1. P-value for an ANOVA or Chi square testing a difference between the samples with 
data at two weeks but not 24 weeks, 24 weeks but not two weeks, and infants who have 
data at both periods.  2. Standard deviation. 3. Infants not included in the other values 




Table 11: Standardized weights for the measurements of inflammatory burden 
 
Inflammation burden at 2 
weeks  
Inflammation burden at 24 
weeks 
 Weight P-value R2  Weight P-value R2 
Neutrophil count 0.345 0.004 0.122  0.420 <0.001 0.177 
CRP 0.804 <0.001 0.646  0.432 <0.001 0.187 





































    Inflammatory burden CRP





burden 1 0.983 0.24 0.43 0.03 
CRP 0.98 1 0.16 0.28 0.04 
AGP 0.24 0.16 1 0.07 -0.01 
Neutrophil 
count 0.43 0.28 0.07 1 -0.01 
Ferretin:TRF 0.03 0.04 -0.01 -0.01 1 
24 weeks 
Inflammatory 
burden 0.05 0.04 0.16 0.06 0 
CRP 0.06 0.06 0.05 0.01 0 
AGP 0.02 0.01 0.16 0.02 0.01 
Neutrophil 
count 0.04 0.02 0.1 0.11 -0.01 














burden 0.05 0.06 0.02 0.04 0.06 
CRP 0.04 0.06 0.01 0.02 0.07 
AGP 0.16 0.05 0.16 0.1 0.01 
Neutrophil 
count 0.06 0.01 0.02 0.11 -0.01 
Ferretin:TRF 0 0 0.01 -0.01 0.18 
24 weeks 
Inflammatory 
burden 1 0.66 0.73 0.65 0.04 
CRP 0.66 1 0.21 0.18 0.06 
AGP 0.73 0.21 1 0.2 0 
Neutrophil 
count 0.65 0.18 0.2 1 0.03 
Ferretin:TRF 0.04 0.06 0 0.03 1 
1. Because values were normalized in the calculation of scores, these correlations are with 
the normalized values. 
2.  The ratio of ferritin to transferrin is included as reference 
3. Bold values represent p-value for the correlation <0.05 
4. Correlations are each calculated with the maximum number of infants available. 
Correlations across time periods can only be calculated within the subset of infants who have 





Table 13: Results of linear regressions considering the relationships between inflammatory burden scores and LAZ. 
Two to six weeks  
  Model 1 
 Model 2  Model 3  Model 4 
Coefficient P-value  Coefficient P-value  Coefficient P-value  Coefficient P-value 
Inflammatory burden -0.188 0.218  -2.693 0.141  -4.672 0.070  -5.0221 0.015 
LNS -0.117 0.195  -0.106 0.241  -0.303 0.017  -0.120 0.184 
 LNS*IB2    0.444 0.190  1.246 0.009  0.377 0.265 
Maternal ART -0.031 0.781  -0.025 0.827  -0.081 0.615  -0.047 0.680 
 Maternal ART*IB    0.631 0.312  0.586 0.506  0.553 0.375 
Infant ART 0.021 0.842  0.032 0.765  -0.035 0.816  0.057 0.595 
 Infant ART*IB    0.213 0.689  0.256 0.733  0.599 0.280 
Illness          0.057 0.676 
 Illness*IB          1.427 0.018 
Birth year -0.221 0.007  -0.218 0.008  -0.371 0.001  -0.230 0.005 
Maternal age 0.002 0.813  0.002 0.864  0.019 0.132  0.000 0.970 
Maternal height 0.028 0.001  0.027 0.001  0.047 0.000  0.028 0.001 
Mother completed more 
than primary school  0.064 0.495 
 0.071 0.451  0.180 0.176  0.061 0.519 
Female  0.305 0.001  0.310 0.001  0.389 0.002  0.325 0.000 
Baseline PI3 1.367 0.000  1.345 0.000  0.297 0.234  1.397 0.000 
 PI*IB    0.810 0.273  1.406 0.176  1.591 0.048 
Baseline LAZ 0.767 <0.001  0.759 0.000     0.762 0.000 
Weeks between 
measures -0.366 0.154 
 -0.358 0.163  0.024 0.946  -0.339 0.184 
Adjusted R2 0.565  0.566  0.139  0.572 
P-value of F-test 
removing inflammatory 
burden 







24 to 28 weeks  
  Model 1  Model 2  Model 3  Model 4 
  Coefficient P-value  Coefficient P-value  Coefficient P-value  Coefficient P-value 
Inflammatory burden 0.343 0.062  -1.774 0.320  -3.533 0.157  -1.766 0.328 
LNS 0.109 0.140  0.115 0.120  0.085 0.409  0.112 0.130 
 LNS*IB    -0.711 0.075  0.165 0.766  -0.731 0.068 
Maternal ART -0.070 0.463  -0.067 0.482  -0.054 0.686  -0.066 0.484 
 Maternal ART*IB    -0.325 0.518  -0.583 0.407  -0.320 0.541 
Infant ART -0.106 0.241  -0.113 0.214  -0.144 0.257  -0.117 0.198 
 Infant ART*IB    0.151 0.745  0.530 0.416  0.167 0.729 
Illness          0.081 0.460 
 Illness*IB          -0.032 0.946 
Birth year -0.032 0.607  -0.027 0.662  -0.2302 0.007  -0.020 0.750 
Maternal age -0.001 0.852  -0.001 0.841  0.001 0.915  -0.002 0.830 
Maternal height 0.017 0.014  0.017 0.014  0.047 0.000  0.017 0.015 
Mother completed more 
than primary school  0.086 0.267 
 0.070 0.369  0.104 0.338  0.074 0.344 
Female  0.222 0.003  0.228 0.002  0.481 0.000  0.231 0.002 
Baseline PI 0.949 <0.001  0.923 0.000  -0.211 0.264  0.926 0.000 
 PI*IB    0.875 0.189  1.385 0.138  0.867 0.195 
Baseline LAZ 0.767 <0.001  0.769 0.000     0.768 0.000 
Weeks between measures 0.144 0.184  0.152 0.160  0.101 0.503  0.148 0.172 
Adjusted R2 0.544  0.548  0.112  0.547 
P-value of F-test removing 






1. Bold values represent p-value<0.05 
2. Inflammatory burden score 






Table 14: Results of linear regressions considering the relationships between inflammatory burden scores and WLZ 
Two to six weeks  
  Model 1  Model 2  Model 3  Model 4 
  Coefficient P-value  Coefficient P-value  Coefficient P-value  Coefficient P-value 
Inflammatory burden 0.254 0.221  1.230 0.085  0.757 0.317  1.6681 0.028 
LNS 0.200 0.103  0.187 0.129  0.218 0.096  0.201 0.103 
 LNS*IB2    -0.489 0.284  -0.610 0.211  -0.412 0.369 
Maternal ART 0.070 0.651  0.031 0.842  0.099 0.548  0.039 0.803 
 Maternal ART*IB    -1.326 0.095  -0.752 0.372  -1.486 0.063 
Infant ART 0.082 0.573  0.053 0.719  0.083 0.591  0.028 0.850 
 Infant ART*IB    -0.742 0.297  -0.353 0.640  -1.199 0.114 
Illness    
  
    0.002 0.992 
 Illness*IB    
  
    -1.304 0.084 
Birth year 0.229 0.511  0.230 0.038  0.412 0.000  0.247 0.027 
Maternal age -0.008 0.022  -0.007 0.577  -0.004 0.762  -0.005 0.679 
Maternal height -0.025 0.415  -0.024 0.033  -0.023 0.053  -0.024 0.029 
Mother completed more 
than primary school  -0.105 0.054  
-0.099 0.442 
 -0.145 0.288  -0.081 0.532 
Female  -0.238 <0.001  -0.242 0.051  -0.341 0.009  -0.252 0.045 
Baseline WLZ 0.335 0.324  0.342 0.000     0.334 0.000 
Weeks between measures 0.343 0.038  0.326 0.349  0.250 0.501  0.304 0.383 
Adjusted R2 0.175  0.176  0.067  0.179 
P-value of F-test removing 
inflammatory burden 0.221 
 0.295  0.653  0.055 
1. Bold values represent p-value<0.05 






24 to 28 weeks  
  Model 1  Model 2  Model 3  Model 4 
  Coefficient P-value  Coefficient P-value  Coefficient P-value  Coefficient P-value 
Inflammatory burden -0.027 0.889  -0.844 0.031  -0.877 0.119  -0.667 0.135 
LNS -0.099 0.194  -0.098 0.201  -0.046 0.672  -0.095 0.213 
 LNS*IB    0.850 0.038  0.493 0.402  0.859 0.037 
Maternal ART 0.087 0.380  0.084 0.395  0.166 0.240  0.082 0.402 
 Maternal ART*IB    0.843 0.102  0.565 0.446  0.715 0.184 
Infant ART 0.057 0.548  0.057 0.545  0.128 0.343  0.050 0.599 
 Infant ART*IB    0.631 0.173  0.807 0.226  0.520 0.282 
Illness    
  
    0.054 0.634 
 Illness*IB    
  
    -0.432 0.373 
Birth year -0.026 0.677  -0.025 0.686  0.180 0.043  -0.020 0.750 
Maternal age -0.002 0.740  -0.002 0.768  -0.002 0.852  -0.003 0.733 
Maternal height -0.004 0.574  -0.005 0.493  0.001 0.938  -0.005 0.502 
Mother completed more 
than primary school  -0.041 0.613  
-0.016 0.840 
 -0.093 0.420  -0.007 0.931 
Female  -0.004 0.957  -0.009 0.907  -0.132 0.227  -0.004 0.957 
Baseline WLZ 0.761 <0.001  0.765 0.000     0.767 0.000 
Weeks between measures -0.100 0.374   -0.116 0.302   -0.058 0.720   -0.116 0.301 
Adjusted R2 0.511  0.516  -0.004  0.515 
P-value of F-test removing 
inflammatory burden 0.889   0.087   0.624   0.173 
1. Bold values represent p-value<0.05   
















Supplemental figure 1: Distributio s f inflam atory burden and its ormalized easures.

































































Figure 7: Difference in inflammatory burden by BAN treatment arm 
 



















































































































































Figure 8: Predicted infant size by inflammatory burden and terms it is interacted with in model two 
Predicted size is calculated using the regression coefficients for model two. Calculations are for a male infant born in 2005 whose 
mother did not complete more than primary school. The infant is assumed to have mean baseline LAZ/WLZ, maternal age, maternal 
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Figure 1: Predicted infant size by inflammatory profile and terms inflammation is interacted with.
1. Predicted size is calculated using the regression coefficients for model two. Calculations are for a male infant born in 2005 whose mother did not complete more than 





Figure 9: Predicted infant size by inflammatory burden and terms it is interacted with in model three 
 
Predicted size is calculated using the regression coefficients for model three, which does not include baseline LAZ/WLZ. Calculations 
are for a male infant born in 2005 whose mother did not complete more than primary school. The infant is assumed to have mean 
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Supp. figure 3: Predicted infant size by inflammatory profile and terms inflammation is interacted with 
without controlling for baseline anthropometry.
1. Predicted size is calculated using the regression coefficients for model three which does not include baseline LAZ/WLZ. Calculations are for a male infant born in 2005 whose 




















Figure 10: Predicted infant size by inflammatory burden and terms it is interacted with in 
model four 
 
Predicted size is calculated using the regression coefficients for model four. Calculations are for 
a male infant born in 2005 whose mother did not complete more than primary school. The infant 
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Supp. Figure 4: Predicted infant size by inflammatory profile, recent illness, and terms inflammation is 
interacted with.
1. Predicted size is calculated using the regression coefficients for model four. Calculations are for a male infant born in 2005 whose mother did not complete more than 
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Supplemental materials 1: Additional information regarding the function of inflammatory 
markers.  
CRP and AGP are acute phase proteins predominantly produced in the liver. However, 
they operate on slightly different time scales in relation to triggers of inflammation. CRP rises 
rapidly in responses to tissue damage, infection, and other biological irritants.162–164162–164 CRP 
responds less strongly to local viral infections than bacterial infection or other inflammatory 
triggers.164164 Although major rises in CRP signify trauma or infection, smaller increases are 
associated with metabolic disturbances and stress.163163 CRP is also produced in adipose 
tissue. AGP is an acute phase protein similar to CRP, regulated by many of the same 
molecules, and responsive to many of the same stimuli: tissue damage, bacterial infection, and 
other biological irritants.165165 AGP may also be regulated by growth hormone.165165 Compared to 
CRP, AGP levels rise more slowly and stay elevated longer.166166 AGP is largely involved in 
immunomodulatory activities and is integral in maintaining homeostasis.165  
Ferritin is the body’s storage mechanism for iron within cells. Similar to acute phase 
proteins, serum ferritin increases during infection and inflammation.166 Levels of ferritin rise 
rapidly, like CRP, and remain elevated, like AGP.166 Serum ferritin itself may act as an acute 
phase protein.166 Many of the same cytokines that regulate CRP and AGP may also regulate 
ferritin levels.166 However, serum ferritin could simply be the result of damaged cells leaking 
their contents.167 The ratio of transferrin to log(ferritin) is often used as an inflammation 
independent measure of iron stores. Here, we build on the work of Skinner et al and use the 






Neutrophil count responds to systemic inflammation and dysregulation of host response 
caused by infection, trauma and burns, and other illnesses.169 Neutrophils are critical to the 
resolution of inflammation.170 They are released from bone marrow in response to infection and 
injury.171 Their lifespan varies based on the local environment and inflammatory signals.169,171 
Neutrophil count is also regulated by many of the same actors as AGP and CRP.165,169 Only 
























CHAPTER 6: Synthesis 
Overview of major research findings 
 This work used data from the Breastfeeding, Antiretroviral, and Nutrition (BAN) study in 
Malawi and the Kigali Antiretroviral and Breastfeeding Assessment of the Elimination of HIV 
(Kabeho) in Rwanda to examine the growth patterns of HIV-exposed and -uninfected infants in 
these two countries. Growth patterns were first examined through a comparison of the growth 
trajectories of the infants who participated in these two studies. This comparison identified 
similarities in the development of a discordant growth pattern, characterized by low length-for-
age and elevated weight-for-length. It further showed that risk factors for some growth patterns 
are variable by study. Next, the interrelationship between viral suppression, maternal weight 
change, breastfeeding, and infant growth was examined within the Kabeho study. We 
concluded that exposure to ART and/or HIV may have negative effects on infant linear growth. 
We further demonstrated the link between maternal and infant health, showing the possibility of 
an environmental factor which supports positive maternal weight change and reduces deficits in 
infant length. Finally, we showed that inflammation and HIV treatment approaches relate to HEU 
infant growth.  
Comparison of growth patterns 
 We used SITAR and latent class growth mixture modeling to compare the growth 
patterns of HEU infants in Malawi and Rwanda in order to determine the extent to which findings 
from one context can be generalized to another. We show considerable similarities in the growth 
of the HEU infants who participated in the BAN and Kabeho studies. The identification of similar 
growth trends despite differences in the socioecological context and HIV-treatment approach 




descriptively in the similarly low length-for-age and elevated relative weight of HEU infants in 
some studies and supported by our detailed statistical comparison.14–16 Such a common 
phenotype could be informative as experts attempt to interpret results from the growing number 
of studies conducted within different countries, contexts, and treatment protocols.  
 Length, linear growth velocity, and the rate of weight gain of the infants in these studies 
are similar. There is no difference in odds of latent growth trajectory by country of origin. 
However, Rwandan infants may be heavier than Malawian infants. Furthermore, the main 
predictors of growth trajectories, neonatal WAZ, maternal age, and maternal height, have 
variable relationships with growth by country of origin. Work using similar methods in high 
income settings found that risk factors for poor growth had similar effects across countries.122 
The variability that we identify may reflect the larger differences in maternal, baseline, and 
context level characteristics which we consider.  
Viral suppression, maternal weight change, breastfeeding, and infant growth 
 Because maternal and infant health are linked through breastfeeding and maternal 
nutritional status,126,127126,127 we used a structural equation model to examine the relationship 
between viral suppression, maternal weight change, breastfeeding, and infant length. HIV 
progression could induce weight loss or weight stability could support the immune system and 
prevent progression. Viral suppression could decrease infant HIV exposure and transmission of 
HIV related opportunistic infections. Related improvements in maternal health may also improve 
infant health. Breastfeeding could induce maternal weight loss or maternal weight loss could 
cause breastfeeding cessation. Furthermore, breastfeeding could support infant growth and 
rapidly growing infants may breastfeed more. Maternal weight could be related to infant growth 
through as yet unestablished pathways other than breastfeeding as well. Our longitudinal 
approach to structural equation modeling allows us to investigate these various hypotheses, 




explanations are most plausible within our population. We found evidence of three of the 
pathways hypothesized above functioning, although in different ways than expected.  
Infants of mothers who are virally suppressed or have been on ART for longer periods 
tend to be shorter at three months. If ART exposure is harmful, the viral suppression achieved 
through increased ART adherence may have negative effects on infant growth rather than the 
positive effects hypothesized. It is likely that these effects dissipate after exposure has ended. 
The effect of ART exposure on infant health and wellbeing remains unclear and represents an 
ongoing public health concern.10,12,15,59,63,64 
In addition, infants who are taller at 12 months are more likely to breastfeed at this age. 
However, continued breastfeeding at 18 months is related to shorter stature. Previous work 
indicates that the negative relationship between continued breastfeeding and size is not simply 
the result of residual confounding with poverty-related factors.146 Nonetheless, extended 
breastfeeding is associated with poverty as women experiencing food shortages will use any 
resource available to feed their infants. As such, the relationships between breastfeeding and 
length at 12 and 18 months should be interpreted cautiously and in the context of extended HIV 
and ART exposure, altered dietary patterns related to continued breastfeeding, socioeconomic 
covariates of extended breastfeeding, and collinearity between breastfeeding and food security. 
Causality should not be inferred.  
More positive maternal weight change is related to increased length at the end of each 
period. The effect of maternal weight change on infant growth after birth has not yet been clearly 
established.110 However, there is some evidence that, in the context of HIV, maternal weight 
loss may be related to slower linear growth.112 We showed that the mechanisms by which this 





Inflammation and growth 
 Inflammation may be related to poor growth outcomes in low resource settings.149–152 
Furthermore, HEU infants have altered immune and inflammatory profiles compared to HUU 
infants.82–84,148 HEU infants also tend to experience poor growth outcomes. Therefore, we 
investigate the relationship between inflammation and growth within HEU infants. This 
relationship could be modified by the added burden of ART and viral exposure. We considered 
the relationship between inflammation and growth over a four week period in the context of ART 
and maternal supplementation.  
We found that the relationship between inflammation and growth in LAZ and WLZ from 
two to six and 24 to 28 weeks was modified by exposure to maternal supplementation and ART. 
We further demonstrate that the effects of inflammation on growth may be chronic, rather than a 
short term consequence of recent illness. The underlying etiology of inflammation, whether it is 
due to recent illness or other factors, alters the relationship between inflammation and growth.  
Strengths and limitations 
The use of these two, expansive datasets allows for the comparison of growth 
trajectories across contexts and the examination of research questions which cannot be 
answered within only one of these studies. However, the differences in the contexts in which 
these studies took place must be acknowledged when interpreting results. This is especially true 
in light of the results of the first aim of this dissertation, which indicate that caution should be 
taken when generalizing results from one study or context to another. A formal comparison of 
the two studies has already been presented in chapter one and will not be repeated here.  
The power of all analyses in this body of work is limited by sample size. While both 
studies are large within their field, they remain relatively small from a statistical standpoint. As 
such, the lack of an identified, statistically significant association in any of these analyses should 




absence. It could simply be the result of a lack of power. However, identified relationships are 
considered to be accurate reflections of true associations.   
The observational nature of Kabeho makes attributing causality inappropriate for all 
analyses. Furthermore, while BAN was a randomized controlled trial, many of our analyses 
consider aspects of the study which were not randomized. In these cases, discussion of 
causation is also avoided. While randomized controlled trials for the formal investigations of 
causality are of public health importance, they are often simply not feasible. This is true for 
many of the exposures examined here, such as time on ART, breastfeeding status, maternal 
height and education, and inflammation. In some cases, there are ethical concerns regarding 
randomization and in others there are simply practical impossibilities. Because of these 
limitations, we must leverage observational data to build large evidence bases that can be 
considered in full to identify likely causal mechanisms and promising avenues of intervention. 
We hope that this work adds to the growing evidence base about the growth and wellbeing of 
HIV-exposed and -uninfected infants.  
Due to the lack of randomized controlled trials regarding the effects of many of the 
exposures considered here on HEU infant growth, this work employs several advanced 
statistical techniques to consider potential associations. These innovative approaches represent 
the dominant strength of this body of work. They allow for the examination of growth and its 
potential determinants in more detail than traditional methods. We are able to consider growth 
trajectories rather than simply growth outcomes. We examine longitudinal interrelationships 
between characteristics of the mother-infant dyad rather than limiting ourselves to consecutively 
examining single aspects of these relationships through linear regression. And, we consider 






This work can be used to inform researchers and public health officials about the growth 
of HEU infants in two low resource settings. Hopefully, it will bring attention to the unique health 
challenges faced by this vulnerable population. Broadly, we show that, while HEU infants may 
experience some similarities in their growth trajectories, populations of HEU infants face unique 
risk factors for certain growth patterns. HEU infant growth outcomes may be related to exposure 
to certain treatment regimens, and this relationship may be altered by inflammatory profiles.  
Our results are of public health significance because they indicate that, despite 
similarities in growth trajectories, risk factors for poor growth are variable by country and 
context. As such, caution must be taken when generalizing results of intervention studies from 
one country or context to another. Such caution is of the utmost importance as there is an ever 
growing body of literature considering the health and wellbeing of HEU infants under a variety of 
context, treatment exposures, and feeding guidelines. As public health officials consider the 
development of protocols within their own domains, they must understand the importance of 
their context in determining the ultimate impact of their recommendations. Because risk factors 
for certain growth trajectories vary by context, the interventions required to support healthy 
growth must also vary by context. While we should, of course, learn from previous studies, 
interventions should always be re-evaluated when applied to new contexts.  
Our structural equation model further highlights the importance of treatment regimens 
and nutrition in determining HEU infant growth. We demonstrate the possibility that ART and/or 
HIV exposure may affect infant linear growth. In addition, we show a relationship between 
maternal weight change and infant length. This link likely acts through a protective 
environmental factor, not breastfeeding. The existence of such a factor demonstrates the public 
health importance of a unified approach to the health of the mother-infant dyad rather than 




Finally, we show that inflammation may modify the effect of HIV management 
approaches on infant growth. Because of the widespread availability of care, it is necessary that 
we fully understand the true impacts of exposure to various HIV related interventions on infant 
health. We also demonstrated the chronic nature of the relationship between inflammation and 
growth. Nonetheless, inflammation in the proper context, recent illness, may be a sign of a well-
functioning immune system and is not necessarily harmful. 
Future directions  
In the future, effort should be made to compare the growth trajectories of HEU and HUU 
infants so that we can determine the extent to which similar growth trajectories are driven by the 
environment or HIV-exposure. We should attempt to identify the long-term health consequences 
of specific growth trajectories and work to find unique and modifiable risk factors for harmful 
growth trajectories. Researchers should further investigate the possibility that exposure to ART 
and/or HIV, in-utero or through breastmilk, may be harmful to infant growth. We advocate for 
RCTs comparing the relative health effects of alternate treatment approaches for the mother-
infant dyad as a whole. Furthermore, they should attempt to identify the protective factor linking 
maternal weight change and infant length. This factor may prove to be a useful target for 
intervention if it is modifiable. We must further investigate the longitudinal development of a 
healthy inflammatory profile within the context of HIV exposure. Public health officials should 






1. Centeral Intelligence Agency. Malawi. World factbook (2018). 
2. Centeral Intelligence Agency. Rwanda. World factbook (2018). 
3. National Statistical Office of Malawi. Malawi Demographic and Health Survey. Natl. Stat. 
Off. DHS Progr. 1–658 (2017). doi:http://www.measuredhs.com/ 
4. Levy, J. M., Webb, A. L. & Sellen, D. W. ‘On our own, we can’t manage’: Experiences 
with infant feeding recommendations among Malawian mothers living with HIV. Int. 
Breastfeed. J. 5, 1–8 (2010). 
5. Bentley, M. E. et al. Perceptions of the role of maternal nutrition in HIV-positive breasf-
feeding women in Malawi. Am. Soc. Nutr. Sci. 945–949 (2005). 
6. Kumbani, L., Bjune, G., Chirwa, E., Malata, A. & Odland, J. Ø. Why some women fail to 
give birth at health facilities: a qualitative study of women’s perceptions of perinantal care 
from rural Southern Malawi. Can. Entomol. 6, 2–5 (1874). 
7. National Institute of statistics, Ministry of Health & ICF International. Rwanda 
Demographic and Health Survey. Rwanda (NISR, MOH, and ICF International, 2015). 
doi:March, 2016 
8. United Nations Development Programme, U. N. D. P. Table 1: Human development index 
and its components. (2018). 
9. UNAIDS. Latest statistics on the status of the AIDS epidemic. (2018). Available at: 
http://www.unaids.org/en/resources/fact-sheet. (Accessed: 7th May 2018) 
10. Evans, C., Jones, C. E. & Prendergast, A. J. HIV-exposed Uninfected Infants: New 
Global Challenges in the Era of Paediatric HIV Elimination. Lancet Infect. Dis. 16, e92–
e107 (2016). 
11. Filteau, S. The HIV Exposed, Uninfected African Child. Trop. Med. Int. Heal. 14, 276–287 
(2009). 
12. Desmonde, S., Goetghebuer, T., Thorne, C. & Leroy, V. Health and survival of HIV 
perinatally exposed but uninfected children born to HIV-infected mothers. Curr. Opin. HIV 
AIDS 11, 465–476 (2016). 
13. Afran, L. et al. HIV-exposed uninfected children: A growing population with a vulnerable 
immune system? Clin. Exp. Immunol. 176, 11–22 (2014). 
14. Jumare, J. et al. Compromised Growth among HIV Exposed Uninfected Compared to 
Unexposed Children in Nigeria. Pediatr. Infect. Dis. J. 38, 1 (2019). 
15. Flax, V. L. et al. Lipid-Based Nutrient Supplements Are Feasible As a Breastmilk 





16. Lane, C., Bobrow, E., Ndatimana, D., Nadyisaba, G. & Adair, L. Determinants of growth 
in HIV-exposed and -uninfected infants in the Kabeho Study. Matern. Child Nutr. e12776 
(2019). 
17. Dewey, K. G. & Begum, K. Long-term consequences of stunting in early life. Matern. 
Child Nutr. 7, 5–18 (2011). 
18. Adair, L. S. Long-term consequences of nutrition and growth in early childhood and 
possible preventive interventions. Nestle Nutr. Inst. Workshop Ser. 78, 111–120 (2014). 
19. Lumeng, J., Taveras, E., Birch, L. & Yanovski, S. Prevention of obesity in infancy and 
early childhood. JAMA Pediatr. 168, (2015). 
20. Weng, S. F., Redsell, S. A., Swift, J. A., Yang, M. & Glazebrook, C. P. Systematic review 
and meta-analyses of risk factors for childhood overweight identifiable during infancy. 
Arch. Dis. Child. 97, 1019–1026 (2012). 
21. Slining, M. et al. Infant Overweight Is Associated with Delayed Motor Development. J. 
Pediatr. 157, 20–25 (2010). 
22. Krombholz, H. Physical Performance in Relation to Age, Sex, Birth Order, Social Class, 
and Sports Activities of Preschool Children. Percept. Mot. Skills 102, 477–484 (2006). 
23. Martorell, R. et al. Weight Gain in the First Two Years of Life Is an Important Predictor of 
Schooling Outcomes in Pooled Analyses from Five Birth Cohorts from. J. Nutr. 140, 348–
354 (2010). 
24. Walker, S. P. et al. Child development: risk factors for adverse outcomes in developing 
countries. Lancet 369, 145–157 (2016). 
25. Grantham-McGregor, S. et al. Developmental potential in the first 5 years for children in 
developing countries. Lancet 369, 60–70 (2007). 
26. De Beer, M. et al. Associations of infant feeding and timing of linear growth and relative 
weight gain during early life with childhood body composition. Int. J. Obes. 39, 586–592 
(2015). 
27. Gishti, O. et al. Fetal and Infant Growth Patterns Associated With Total and Abdominal 
Fat Distribution in School-Age Children. J. Clin. Endocrinol. Metab. 99, 2557–2566 
(2014). 
28. Sovio, U. et al. How do changes in body mass index in infancy and childhood associate 
with cardiometabolic profile in adulthood Findings from the northern Finland birth cohort 
1966 study. Int. J. Obes. 38, 53–59 (2014). 
29. Antonisamy, B. et al. Weight gain and height growth during infancy, childhood, and 
adolescence as predictors of adult cardiovascular risk. J. Pediatr. 180, 53–61 (2016). 
30. Black, R. E. et al. Maternal and child undernutrition and overweight in low-income and 




31. Brands, B., Demmelmair, H. & Koletzko, B. How growth due to infant nutrition influences 
obesity and later disease risk. Acta Paediatr. Int. J. Paediatr. 103, 578–585 (2014). 
32. Dewey, K. G. Reducing stunting by improving maternal, infant and young child nutrition in 
regions such as South Asia: evidence, challenges and opportunities. Matern. Child Nutr. 
12, 27–38 (2016). 
33. Kuchenbecker, J. et al. Exclusive breastfeeding and its effect on growth of Malawian 
infants: results from a cross-sectional study. Paediatr. Int. Child Health 35, 14–23 (2015). 
34. Wright, M., Bentley, M., Mendez, M. & Adair, L. The interactive association of dietary 
diversity scores and breast-feeding status with weight and length in Filipino infants aged 
6-24 months. Public Health Nutr. 18, 1762–1773 (2015). 
35. Kamudoni, P., Maleta, K., Shi, Z. & Holmboe-Ottesen, G. Exclusive breastfeeding 
duration during the first 6 months of life is positively associated with length-for-age among 
infants 6-12 months old, in Mangochi district, Malawi. Eur. J. Clin. Nutr. 69, 96–101 
(2015). 
36. Eriksen, K. G. et al. Following the World Health Organization’s Recommendation of 
Exclusive Breastfeeding to 6 Months of Age Does Not Impact the Growth of Rural 
Gambian Infants. J. Nutr. 147, 248–255 (2017). 
37. Owais, A. et al. Minimum acceptable diet at 9 months but not exclusive breastfeeding at 3 
months or timely complementary feeding initiation is predictive of infant growth in rural 
Bangladesh. PLoS One 11, 1–10 (2016). 
38. Engebretsen, I. M. S. et al. Growth effects of exclusive breastfeeding promotion by peer 
counsellors in sub-Saharan Africa: The cluster-randomised PROMISE EBF trial. BMC 
Public Health 14, 1–12 (2014). 
39. Victora, C. G. et al. Breastfeeding in the 21st Century: Epidemiology, Mechanisms, and 
Lifelong Effect. Lancet 387, 475–490 (2016). 
40. Onyango, A. W., Borghi, E., De Onis, M., Del Carmen Casanovas, M. & Garza, C. 
Complementary feeding and attained linear growth among 6-23-month-old children. 
Public Health Nutr. 17, 1975–1983 (2014). 
41. Saaka, M. Maternal and Infant Factors Associated with Child Growth in the First Year of 
Life. Sci. J. Public Heal. 3, 775 (2015). 
42. Iannotti, L. L. et al. Eggs in Early Complementary Feeding and Child Growth: A 
Randomized Controlled Trial. Pediatrics 140, e20163459 (2017). 
43. Stewart, C. P. et al. The effect of eggs on early child growth in rural Malawi: the Mazira 
Project randomized controlled trial. Am. J. Clin. Nutr. 110, 1026–1033 (2019). 
44. Stephenson, K. B. et al. Complementary feeding with cowpea reduces growth faltering in 





45. Ashorn, P. et al. Supplementation of Maternal Diets during Pregnancy and for 6 Months 
Postpartum and Infant Diets Thereafter with Small-Quantity Lipid-Based Nutrient 
Supplements Does Not Promote Child Growth by 18 Months of Age in Rural Malawi: A 
Randomized Controlled Tria. J. Nutr. 145, 1345–1353 (2015). 
46. Ashorn, P. et al. The impact of lipid-based nutrient supplement provision to pregnant 
women on newborn size in rural Malawi : a randomized controlled trial 1 – 4. Am. J. Clin. 
Nutr. 101, 387–397 (2015). 
47. Hess, S. Y. et al. Small-quantity lipid-based nutrient supplements, regardless of their zinc 
content, increase growth and reduce the prevalence of stunting and wasting in young 
burkinabe children: A cluster-randomized trial. PLoS One 10, 1–19 (2015). 
48. Mangani, C. et al. Effect of complementary feeding with lipid-based nutrient supplements 
and corn-soy blend on the incidence of stunting and linear growth among 6- to 18-month-
old infants and children in rural Malawi. Matern. Child Nutr. 11, 132–143 (2015). 
49. Skau, J. K. H. et al. Effects of animal source food and micronutrient fortification in 
complementary food products on body composition , iron status , and linear growth : a 
randomized trial in Cambodia 1 – 4. Am. J. Clin. Nutr. 101, 742–751 (2015). 
50. Brennan, A. T. et al. A Meta-analysis Assessing All-cause Mortality in HIV-exposed 
Uninfected Compared with HIV-Unexposed Uninfected Infants and Children. AIDS 30, 
2351–2360 (2016). 
51. Slogrove, A. L. Pattern of Infectious Morbidity in HIV-exposed Uninfected infants and 
Children. Front. Immunol. 7, 164 (2016). 
52. Pierre, R. et al. Infectious Disease Morbidity and Growth Among Young HIV-exposed and 
Uninfected Children in Jamaca. Rev. Panam. Salud Publica 40, 401–409 (2016). 
53. Goldberg, R. E. & Short, S. E. What do we know about children living with HIV- infected 
or AIDS-ill adults in Sub-Saharan Africa ? A systematic review of the literature What do 
we know about children living with HIV-infected or AIDS-ill adults in Sub-. AIDS Care 28, 
130–141 (2016). 
54. Rosala-Hallas, A., Bartlett, J. W. & Filteau, S. Growth of HIV-exposed uninfected, 
compared with HIV-unexposed, Zambian children: A longitudinal analysis from infancy to 
school age. BMC Pediatr. 17, 1–9 (2017). 
55. Lartey, A., Marquis, G., Perez-Escamilla, R., Brakohiapa, L. & Ampofo, W. Maternal HIV 
is Associated with Reduced Growth in the First Year of Life among Infants in the Eastern 
Region of Ghana: The Research to Improve Infant Nutrition and Growth (RING) Project. 
Matern. Child Nutr. 10, 604–616 (2014). 
56. Sudfeld, C. et al. Linear growth faltering among HIV-expsoed uninfected children. J Aquir 
Immune Defic Syndr 25, 368–379 (2015). 
57. Rossouw, M. E., Cornell, M., Cotton, M. F. & Esser, M. M. Feeding practices and 
nutritional status of HIV-exposed and HIV-unexposed infants in the Western Cape. South. 




58. Kamateeka, M. & Sebikari, D. It is Time to Explore the Potential Benefit of Routine 
Micronutrient Supplementation in Optimizing Bone Health and Growth in HIV Exposed 
Uninfected Children in the Context of Early Antiretroviral Exposure in Resource Limited 
Settings. HIV/AIDS Res. Treat. – Open J. 4, e1–e4 (2017). 
59. Flax, V. L. et al. Use of Lipid-Based Nutrient Supplements by HIV-Infected Malawian 
Women during Lactation Has No Effect on Infant Growth from 0 to 24 Weeks. J. Nutr. 
142, 1350–1356 (2012). 
60. Becquet, R. et al. Complementary feeding adequacy in relation to nutritional status 
among early weaned breastfed children who are born to HIV - infected mothers : ANRS 
1201 / 1202 Ditrame Plus , Abidjan , Cote d ’ Ivoire. Pediatrics 117, e701–e710 (2006). 
61. McHenry, M. S. et al. Neurodevelopment in Young Children Born to HIV-Infected 
Mothers: A Meta-analysis. Pediatrics 141, (2018). 
62. Chaudhury, S. et al. Neurodevelopment of HIV-exposed and HIV-unexposed uninfected 
children at 24 months. Pediatrics 140, (2017). 
63. Powis, K. et al. Effects of in Utero Antiretroviral Exposure on Longitudinal Growth of HIV-
exposed Uninfected Infants in Botswana. J. Acquir. Immune Defic. Syndr. 56, 131–138 
(2011). 
64. Denneman, L. et al. Exposure to improved nutrition from conception to age two years and 
adult cardiometabolic disease risk. Lancet Glob. Heal. in press, e875–e884 (2018). 
65. Keino, S., Plasqui, G., Ettyang, G. & Van Den Borne, B. Determinants of stunting and 
overweight among young children and adolescents in sub-Saharan Africa. Food Nutr. 
Bull. 35, 167–178 (2014). 
66. Rachmi, C. N., Agho, K. E., Li, M. & Baur, L. A. Stunting coexisting with overweight in 
2·0-4·9-year-old Indonesian children: Prevalence, trends and associated risk factors from 
repeated cross-sectional surveys. Public Health Nutr. 19, 2698–2707 (2016). 
67. Symington, E. A., Gericke, G. J., Nel, J. H. & Labadarios, D. The relationship between 
stunting and overweight among children from South Africa: Secondary analysis of the 
national food consumption survey - Fortification baseline I. South African Med. J. 106, 
65–69 (2016). 
68. Saaka, M. & Galaa, S. Z. Relationships between Wasting and Stunting and Their 
Concurrent Occurrence in Ghanaian Preschool Children. J. Nutr. Metab. 2016, (2016). 
69. Walrod, J. et al. Community factors associated with stunting, overweight and food 
insecurity: A community-based mixed-method study in four Andean indigenous 
communities in Ecuador. BMJ Open 8, 1–11 (2018). 
70. Barth-Jaeggi, T. et al. In-home fortification with 2.5mg iron as NaFeEDTA does not 
reduce anaemia but increases weight gain: A randomised controlled trial in Kenyan 
infants. Matern. Child Nutr. 11, 151–162 (2015). 




Overweight and Obesity in a Sample of Urban Malaysian Children. Ecol. Food Nutr. 55, 
378–389 (2016). 
72. Zhang, X., Zhivaki, D. & Lo-man, R. Unique aspects of the perinatal immune system. Nat. 
Publ. Gr. 17, 495–507 (2017). 
73. Gomez de Aguero, M. et al. The maternal microbiota drives early postnatal innate 
immune development. Science (80-. ). 351, 35313–35319 (2016). 
74. Romano-Keeler, J. & Weitkamp, J. Maternal influences on fetal microbila colonization and 
immune development. Pediatr. Res. 77, 189–195 (2015). 
75. Agarwal, S., Karmaus, W., Davis, S. & Gangur, V. Immune Markers in Breast Milk and 
Fetal and Maternal Body Fluids : A Systematic Review of Perinatal Concentrations. J. 
Hum. Lact. 27, 171–186 (2011). 
76. Wong, S. C. et al. Growth and the growth hormone-insulin like growth factor 1 axis in 
children with chronic inflammation: Current Evidence, Gaps in Knowledge, and Future 
Directions. Endocr. Rev. 37, 62–110 (2016). 
77. Crimmins, E. M. & Finch, C. E. Infection , inflammation , height , and longevity. 
Procedings Natl. Acad. Sci. 103, (2005). 
78. Liu, J. et al. Fecal calprotecting levels are higher in rural than in urban Chinese infants 
and negatively associated with growth. BMC Pediatr. 12, 129 (2012). 
79. Campbell, D., Elia, M. & Lunn, P. Growth faltering in rural Gambian infants is associated 
with impaired small intestinal barrier function, leading to endotoxemia and systemic 
inflammation. J. Nutr. 133, 1332–1338 (2003). 
80. Campbell, D., McPhail, G., Lunn, P., Elia, M. & Jeffries, D. Intestingal inflammation 
measured by fecal neopterin in Gambian children with enteropathy: association with 
growth failure, Giardia lamblia, and intestinal permeability. J Pediatr Gastroenterol Nutr 
39, 153–157 (2004). 
81. Goto, R., Mascie-Taylor, C. & Lunn, P. Impact of intestinal permeability, inflammation 
status and parasitic infections on infant growth faltering in rural Bangladesh. Br. J. Nutr. 
101, 1509–1516 (2009). 
82. BA, R. et al. Altered innate immune development in HIV-exposed and uinfected infants. J 
Aquir Immune Defic Syndr 66, 245–255 (2014). 
83. Abu-Raya, B., Kollmann, T. R., Marchant, A. & MacGillivray, D. M. The immune system of 
HIV-exposed uninfected infants. Front. Immunol. 7, 1–10 (2016). 
84. Prendergast, A. J. et al. Intestinal Damage and Inflammatory Biomarkers in Human 
Immunodeficiency Virus (HIV)-Exposed and HIV-Infected Zimbabwean Infants. J. Infect. 
Dis. 216, 651–661 (2017). 
85. Dirajlal-Fargo, S. et al. HIV-exposed-uninfected infants have increased inflammation and 




86. Ewing, A. C. et al. Effects of concurrent exposure to antiretrovirals and cotrimoxazole 
prophylaxis among HIV-exposed, uninfected infants. AIDS 31, 2455–2463 (2017). 
87. Chasela, C. et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N. 
Engl. J. Med. 362, 2271–2281 (2010). 
88. Ruck, C., Reikie, B. A., Marchant, A., Kollmann, T. R. & Kakkar, F. Linking susceptibility 
to infectious diseases to immune system abnormalities among HIV-exposed uninfected 
infants. Front. Immunol. 7, 1–12 (2016). 
89. WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in 
infants. World Health (2006). 
90. World Health Organization. Use of antiretroviral drugs for treating pregnant women and 
preventing HIV infection in infants. Geneva WHO 1–117 (2012). doi:WHO/HIV/2012.6 
91. Schouten, E. J. et al. Prevention of mother-to-child transmission of HIV and the health-
related Millennium Development Goals: Time for a public health approach. Lancet 378, 
282–284 (2011). 
92. Fasawe, O. et al. Cost-Effectiveness Analysis of Option B+ for HIV Prevention and 
Treatment of Mothers and Children in Malawi. PLoS One 8, (2013). 
93. Ahmed, S., Kim, M. H. & Abrams, E. J. Risks and benefits of lifelong antiretroviral 
treatment for pregnant and breastfeeding women: A review of the evidence for the Option 
B+ approach. Curr. Opin. HIV AIDS 8, 474–489 (2013). 
94. UNFPA/UNICEF/WHO/UNAIDS. New data on the prevention of mother-to-child 
transmission of HIV and their policy implications. (2003). 
95. WHO. WHO HIV and Infant Feeding Technical Consultation: Held on behalf of the Inter-
agency Task Team (IATT) on Prevention of HIV Infections in Pregnant Women, Mothers 
and their Infants. Consensus Statement 1–5 (2006). 
96. World Health Organization. Guideline: Updates on HIV and Infant Feeding: Duration of 
Breastfeeding, and Support from Health Services to Improve Feeding Practices among 
Mothers Living with HIV. WHO Publ. 59 (2016). 
97. Shapiro, R. et al. HIV transmission and 24-month survival in a randomized trail of HAART 
to prevent MTCT during pregnancy and breastfeeding in Botswana (The Mma Bana 
Study). AIDS 496, 181–186 (2014). 
98. Gill, M. M. M. et al. 24-month HIV-free survival among infants born to HIV-positive women 
enrolled in Option B+ program in Kigali, Rwanda: The Kabeho Study. Medicine 
(Baltimore). 96, (2017). 
99. Coovadia, H. et al. Mother-to-child transmission of HIV-1 infection during exclusive 
breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 369, 
(2007). 




effectiveness of revised (post-2010) World Health Organization guidelines on prevention 
of mother-to-child transmission of HIV using routinely collected data in sub-Saharan 
Africa. Medicine (Baltimore). 96, e8055 (2017). 
101. Morden, E. et al. Growth of HIV-exposed uninfected infants in the first 6 months of life in 
South Africa: The IeDEA-SA collaboration. PLoS One 11, 1–15 (2016). 
102. Yeganeh, N. et al. Infectious Morbidity, Mortality and Nutrition in HIV-Exposed, 
Uninfected, Formula Fed Infants: Results from the HPTN 040/PACTG 1043 Trial. The 
Pediatric infectious disease journal (2018). doi:10.1097/INF.0000000000002082 
103. Powis, K. et al. In-utero triple antiretroviral exposure associated with decreased growth 
among HIV-exposed uninfected infants in Botswana. AIDS 30, 39–46 (2017). 
104. L., K. Energy expenditure in HIV infection. Am. J. Clin. Nutr. 94, 1677S-1682S (2011). 
105. Mangili, A., Murman, D. H., Zampini, A. M., Wanke, C. A. & Mayer, K. H. Nutrition and 
HIV Infection: Review of Weight Loss and Wasting in the Era of Highly Active 
Antiretroviral Therapy from the Nutrition for Healthy Living Cohort. Clin. Infect. Dis. 42, 
836–842 (2006). 
106. Wheeler, D. A. et al. Weight loss as a predictor of survival and disease progression in 
HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir 
Immune Defic Syndr Hum Retrovirol 18, 80–85 (1998). 
107. Linné, Y., Dye, L., Barkeling, B. & Rössner, S. Long-term weight development in women: 
A 15-year follow-up of the effects of pregnancy. Obes. Res. 12, 1166–1178 (2004). 
108. Haiek, L. N., Kramer, M. S., Ciampi,  a & Tirado, R. Postpartum weight loss and infant 
feeding. J. Am. Board Fam. Pract. 14, 85–94 (2001). 
109. Abebe, D. et al. Developmental trajectories of postpartum weight 3 years after birth: 
Norwegian mother and child cohort study. Matern. Child Nutr. 19, 917–925 (2015). 
110. Wrottesley, S. V., Lamper, C. & Pisa, P. T. Review of the importance of nutrition during 
the first 1000 days: Maternal nutritional status and its associations with fetal growth and 
birth, neonatal and infant outcomes among African women. J. Dev. Orig. Health Dis. 7, 
144–162 (2015). 
111. Wilkinson, A. L. et al. Associations between gestational anthropometry, maternal HIV, 
and fetal and early infancy growth in a prospective rural/semi-rural Tanzanian cohort, 
2012-13. BMC Pregnancy Childbirth 15, 1–13 (2015). 
112. Widen, E. M. et al. Maternal Weight Loss during Exclusive Breastfeeding Is Associated 
with Reduced Weight and Length Gain in Daughters of HIV-Infected Malawian Women. J. 
Nutr. 143, 1168–1175 (2013). 
113. Rupérez, M. et al. Maternal HIV infection is an important health determinant in non-HIV-
infected infants. Aids 31, 1545–1553 (2017). 




chronic disease. Nutrients 10, (2018). 
115. Horst, C. Van Der et al. Modifications of a large HIV prevention clinical trial to fit changing 
realities: A case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) Protocol in 
Lilongwe, Malawi. Contemp Clin Trials 30, 24–33 (2009). 
116. Cole, T. J., Donaldson, M. D. C. & Ben-shlomo, Y. SITAR-a useful instrument for growth 
curve analysis. Int. J. Epidemiol. 39, 1558–1566 (2010). 
117. Cole, T. SITAR. (2018). 
118. Ram, N. & Grimm, K. J. Growth mixture modeling: A method for identifying differences in 
longitudinal change among unobserved groups. Int. J. Behav. Dev. 33, 565–576 (2009). 
119. World Health Organization. WHO Anthro: igrowup. (2011). 
120. Prost-Lima, C., Phillips, V., Diakite, A. & Liquet, B. Lcmm: Extended mixed models using 
latent classes and latent processes. (2017). 
121. Olusanya, B. O. & Renner, J. K. Predictors of growth velocity in early infancy in a 
resource-poor setting. Early Hum. Dev. 87, 647–652 (2011). 
122. Pizzi, C. et al. Prenatal Influences on Size, Velocity and Tempo of Infant Growth: 
Findings from Three Contemporary Cohorts. PLoS One 9, e90291 (2014). 
123. Cole, T. J. & Altman, D. G. Percentage differences, symmetry, and natural logarithms. Br. 
Med. J. 358, 1–2 (2017). 
124. Slogrove, A. et al. Surviving and Thriving—Shifting the Public Health Response to HIV-
Exposed Uninfected Children: Report of the 3rd HIV-Exposed Uninfected Child 
Workshop. Front. Pediatr. 6, 1–5 (2018). 
125. Leroy, J. L. & Frongillo, E. A. Perspective: What Does Stunting Really Mean? A Critical 
Review of the Evidence. Adv. Nutr. 1–9 (2019). doi:10.1093/advances/nmy101 
126. Dieterich, C. M., Felice, J. P., O’Sulliivan, E. & Rasmussen, K. Breastfeeding and Health 
Outcomes fro the Mother-Infant Dyad. Pediatr Clin North Am. 60, 31–48 (2013). 
127. Ramakrishnan, U., Grant, F., Goldenberg, T., Zongrone, A. & Martorell, R. Effect of 
women’s nutrition before and during early pregnancy on maternal and infant outcomes: A 
systematic review. Paediatr. Perinat. Epidemiol. 26, 285–301 (2012). 
128. The Kesho Bora Study Group. Maternal HIV-1 Disease Progression 18 – 24 Months 
Postdelivery According to Antiretroviral Prophylaxis Regimen (Triple-Antiretroviral 
Prophylaxis During Pregnancy and Breastfeeding vs Zidovudine / Single-Dose Nevirapine 
Prophylaxis): The Kesho Bora Random. HIV/AIDS 55, (2012). 
129. Koyanagi, A. et al. Predictive Value of Weight Loss on Mortality of HIV-Positive Mothers 
in a Prolonged Breastfeeding Setting. AIDS Res. Hum. Retroviruses 27, 1141–1148 
(2011). 




RNA in Breast Milk and of Its Relationship to Infant Infection and Maternal Disease. JID 
187, 741–747 (2003). 
131. Kuhn, L. et al. Does Severity of HIV Disease in HIV-infected Mothers Affect Mortality and 
Morbidity among their Uninfected Infants? Clin. Infect. Dis. An Off. Publ. Infect. Dis. Soc. 
Am. 41, 1654–1661 (2005). 
132. Chowdhury, R. et al. Breastfeeding and maternal health outcomes: a systematic review 
and meta-analysis. Acta Paediatr. 104, 96–113 (2015). 
133. Kindra, G., Coutsoudis, A., Esposito, F. & Esterhuizen, T. Breastfeeding in HIV exposed 
infants significantly improves child health: A prospective study. Matern. Child Health J. 
16, 632–640 (2012). 
134. Odom, E. C., Li, R., Scanlon, K. S., Perrine, C. G. & Grummer-Strawn, L. Reasons for 
Earlier Than Desired Cessation of Breastfeeding. Pediatrics 131, e726–e732 (2013). 
135. Wasser, H. et al. Infants Perceived as ‘Fussy’ Are More Likely to Receive 
Complementary Foods Before 4 Months. Pediatrics 127, 229–237 (2011). 
136. Matsuyama, A., Karama, M., Tanaka, J. & Kaneko, S. Perceptions of caregivers about 
health and nutritional problems and feeding practices of infants: A qualitative study on 
exclusive breast-feeding in Kwale, Kenya. BMC Public Health 13, 1–13 (2013). 
137. S.A., R. et al. Parents’ beliefs about appropriate infant size, growth and feeding 
behaviour: implications for the prevention of childhood obesity. BMC Public Health 10, 
711 (2010). 
138. Muthen, L. & Muthen, B. Mplus Users Guide. (Muthen & Muthen). 
139. Maskew, M., Brennan, A. T., MacPhail, A. P., Sanne, I. M. & Fox, M. P. Poorer ART 
outcomes with increasing age at a large public sector HIV clinic in Johannesburg, South 
Africa. J. Int. Assoc. Physicians AIDS Care 11, 57–65 (2012). 
140. Yehia, B. R. et al. Impact of age on retention in care and viral suppression. J. Acquir. 
Immune Defic. Syndr. 68, 413–419 (2015). 
141. Hinkin, C. H. et al. Medication adherence in HIV-infected adults: Effect of patient age, 
cognitive status, and substance abuse. Aids 18, 1–13 (2004). 
142. Maonga, A. R., Mahande, M. J., Damian, D. J. & Msuya, S. E. Factors Affecting Exclusive 
Breastfeeding among Women in Muheza District Tanga Northeastern Tanzania: A Mixed 
Method Community Based Study. Matern. Child Health J. 20, 77–87 (2016). 
143. Kimani-Murage, E. W. et al. Factors affecting actualisation of the WHO breastfeeding 
recommendations in urban poor settings in Kenya. Matern. Child Nutr. 11, 314–332 
(2015). 
144. Kok Leong, T. Factors associated with exclusive breastfeeding among infants under six 




145. Narayan, S., Natarajan, N. & Bawa, K. S. Maternal and neonatal factors adversely 
affecting breastfeeding in the perinatal period. Med. J. Armed Forces India 61, 216–219 
(2005). 
146. Caulfield, L. E., Bentley, M. E. & Ahmed, S. Is prolonged breastfeeding associated with 
malnutrition? Evidence from nineteen demographic and health surveys. Int. J. Epidemiol. 
25, 693–703 (1996). 
147. Lesorogol, C., Bond, C., Dulience, S. & Iannotti, L. Economic determinants of 
breastfeeding in Haiti: The effects of poverty, food insecurity, and employment on 
exclusive breastfeeding in an urban population. Matern. Child Nutr. 14, (2018). 
148. Pfeifer, C. & Bunders, M. J. Maternal HIV infection alters the immune balance in the 
mother and fetus; Implications for pregnancy outcome and infant health. Curr. Opin. HIV 
AIDS 11, 138–145 (2016). 
149. Hautvast, J. L. A., Tolboom, J. J. M., Willems, J. L., Mwela, C. M. & Monnens, L. A. H. 
Consequences of infections for three-month length increment in young children in rural 
Zambia. Acta Paediatr. Int. J. Paediatr. 89, 296–301 (2000). 
150. Syed, S. et al. Biomarkers of systemic inflammation and growth in early infancy are 
associated with stunting in young Tanzanian children. Nutrients 10, 1–14 (2018). 
151. Prendergast, A. J. et al. Stunting is characterized by chronic inflammation in Zimbabwean 
infants. PLoS One 9, (2014). 
152. McDade, T. W., Reyes-García, V., Tanner, S., Huanca, T. & Leonard, W. R. Maintenance 
versus growth: Investigating the costs of immune activation among children in lowland 
Bolivia. Am. J. Phys. Anthropol. 136, 478–484 (2008). 
153. Burke, R. M. et al. Predictors of inflammation in a cohort of bolivian infants and toddlers. 
Am. J. Trop. Med. Hyg. 95, 954–963 (2016). 
154. Campbell, R. K. et al. Environmental enteric dysfunction and systemic inflammation 
predict reduced weight but not length gain in rural Bangladeshi children. Br. J. Nutr. 119, 
407–414 (2018). 
155. Syed, S. et al. Serum anti-flagellin and anti-lipopolysaccharide immunoglobulins as 
predictors of linear growth faltering in Pakistani infants at risk for environmental enteric 
dysfunction. PLoS One 13, 1–13 (2018). 
156. Iqbal, N. T. et al. Promising Biomarkers of Environmental Enteric Dysfunction: A 
Prospective Cohort study in. Sci. Rep. 8, 1–10 (2018). 
157. Ferguson, Y. et al. Evaluating nurses’ implementation of an infant-feeding counseling 
protocol for HIV-infected mothers: The BAN Study in Lilongwe, Malawi. AIDS Educ. 
Prevetion 21, 141–155 (2009). 
158. Dow, A. et al. Effects of cotrimoxazole prphylactic treatment on adverse health outcomes 




159. World Health Organization. Guidelines on co-trimoxazole prophylaxis for HIV-related 
infections among adolescents and adults in resource-limited settings. (2006). 
160. WHO Child Growth Standards based on length/height, weight and age. Acta Paediatr. 
450–476 (2006). 
161. Graham, G. G. & Scott, K. F. Mechanisms of action of paracetamol and related 
analgesics. Inflammopharmacology 11, 401–413 (2003). 
162. Windgassen, E. B., Funtowicz, L., Lunsford, T. N., Harris, L. A. & Mulvagh, S. L. C-
reactive protein and high-sensitivity C-reactive protein: An update for clinicians. Postgrad. 
Med. 123, 114–119 (2011). 
163. Kushner, I., Samols, D. & Magrey, M. A unifying biologic explanation for ‘high-sensitivity’ 
C-reactive protein and ‘low-grade’ inflammation. Arthritis Care Res. 62, 442–446 (2010). 
164. Ansar, W. & Ghosh, S. C-reactive protein and the biology of disease. Immunol. Res. 56, 
131–142 (2013). 
165. Fournier, T., Medjoubi-N, N. & Porquet, D. Alpha-1-acid glycoprotein. Biochim. Biophys. 
Acta - Protein Struct. Mol. Enzymol. 1482, 157–171 (2000). 
166. Northrop-clewes, C. A. The interpretation of indicators of iron status during an acute 
phase response. Assessing the iron status of populations: report of a joint World Health 
Organization/Centers for Disease Control and Prevention technical consultation on the 
assessment of iron status at the population level (2007). 
167. Kell, D. B. & Pretorius, E. Serum ferritin is an important inflammatory disease marker, as 
it is mainly a leakage product from damaged cells. Metallomics 6, 748–773 (2014). 
168. Skinner, A. C., Steiner, M. J., Henderson, F. W. & Perrin, E. M. Multiple Markers of 
Inflammation and Weight Status: Cross-sectional Analyses Throughout Childhood. 
Pediatrics 125, e801–e809 (2010). 
169. McDonald, B. Neutrophils in critical illness. Cell Tissue Res. 371, 607–615 (2018). 
170. Ortega-Gómez, A., Perretti, M. & Soehnlein, O. Resolution of inflammation: An integrated 
view. EMBO Mol. Med. 5, 661–674 (2013). 
171. Kubes, P. The enigmatic neutrophil: what we do not know. Cell Tissue Res. 371, 399–
406 (2018). 
 
 
 
